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 While aerobic glycolysis has been shown to confer advantages in 
tumorigenesis, the molecular mechanisms underlying the regulation of this altered 
cancer metabolism remained elusive. Given that PTEN/Akt is one the of most 
dysregulated pathways in cancers, we sought to determine if there is any cross talk 
between this signaling and metabolism, particularly the mitochondrial respiratory 
functions. Using genetic modified mouse embryonic fibroblast (MEF), we showed 
that MEF with PTEN-/- had increased respiratory capacity, which was regulated 
specifically at translational but not transcriptional level. Dysregulated PTEN/Akt 
signaling in MEF and breast cell lines MCF10CA1a (malignant counterpart of 
MCF10A1) also had enhanced mitochondrial oxidative phosphorylation (OXPHOS) 
coupling (i.e. lower proton leak) mediated via mitochondrial cholesterol. The lower 
proton leak was associated with higher mitochondrial membrane potential (MMP) 
and reactive oxygen species (ROS) production. The increased ROS production in 
PTEN/Akt dysregulated cells had elicited a higher dependency of those cells on 
glutamine metabolism. Given that glutamine metabolism is implicated in redox 
modulation, we further proposed that targeting redox regulation through glutamine 
metabolism has the potential in unveiling the Achilles' heel in cancers. Taken 
together, this study revealed the regulation of respiratory functions by PTEN/Akt 
signaling and its implication in tumorigenesis. 
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CHAPTER 1 INTRODUCTION 
1.1 MOTIVATION OF THE STUDY 
 Conceptual progression in the last decade in cancer metabolism has 
propelled cancer research forward into a new era ever since the discovery of the 
"Warburg effect" (aerobic glycolysis) nearly 80 years ago [1]. Notably, the 
mechanistic concept of the Warburg effect has been accentuated in various 
biomedical applications ranging from the tumor imaging by the 18F-deoxyglucose-
positron emission topography (PET) scan [2] to potential anti-cancer therapeutic 
interventions (e.g. 3-bromopyruvate [3]). While the reprogramming of energy 
metabolism has emerged as one of the hallmarks of cancer [4], it has often being 
regarded as the phenotype orchestrated by oncogenes. The latter enunciates the 
importance in unveiling the stygian link between oncogenes and tumor metabolism. 
Of numerous oncogenes reported, protein kinase B/Akt appears to be one of the 
most critical kinases involved in tumorigenesis owing to its diverse cellular 
functions, ranging from cell survival, growth, proliferation, angiogenesis, 
metabolism to metastasis. Although the effect of Akt on aerobic glycolysis has 
been illustrated [5], its role in respiratory functions remain unknown. The 
respiratory dysfunction has attracted considerable attention in cancer metabolism as 
respiratory injury was hypothesized by Otto Warburg for tumor cells to switch to 
aerobic glycolysis [6].   
 In view of a significant knowledge gap between oncogenic signalings and 
tumor metabolism, this thesis aims to better understand the pleiotropic effects of 
PTEN/Akt on respiratory functions. Using combinatorial approaches, we dissected 
the mechanisms which underlie the regulation of  respiratory functions  by 
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PTEN/Akt signaling and explored the physio-pathological functions of this 
















 This thesis is organized into 7 chapters (chapter 1-7). Chapter 1 outlines the 
motivation of the study driven by the fascinating hypotheses. Chapter 2 provides a 
brief introduction to the contemporary knowledge on PTEN/Akt signaling, tumor 
metabolism and the pathological roles of reactive oxygen species (ROS) in 
tumorigenesis. Chapter 3 reveals the novel regulation of respiratory functions by 
PTEN/Akt signaling distinctively at protein translational but not gene 
transcriptional level. Our findings suggest aerobic glycolysis stimulated by Akt is 
not at the cost of respiratory functions. Chapter 4 explains lower proton leak in 
PTEN/Akt-dysregulated cells is correlated with mitochondrial cholesterol content. 
The lower proton leak mediated by cholesterol has important physiological 
function of regulating mitochondrial membrane potential which serves as a driving 
force for ROS generation. Chapter 5 demonstrates PTEN/Akt regulates glutamine 
addiction in highly proliferative cells. The higher glutamine dependency maybe 
involve in tempering the oxidative stress. We further suggest that targeting redox 
homeostasis via glutamine metabolism in cancers with PTEN/Akt aberration may 
possess therapeutic benefit. Chapter 6 elucidates the necessity of modifying the 
cytochrome c oxidase activity assay due to problems encountered in current 
protocols. In addition to high sensitivity and accuracy, the modified assay has 
promising diagnostic potential due to its wide application to different types of 
sample, ranging from C.elegans, culture cells to human platelets. Owing to the 
superior features of our modified assay, our data further unveiled that COX activity 
might be one of the "biomarkers for aging". Last but not least, chapter 7 
summarizes the data presented in this work, and discusses further directions of 
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PTEN/Akt signaling on respiratory functions, as well as the general outlooks in 
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CHAPTER 2 LITERATURE REVIEW 
 
2.1 PTEN/PI3K/AKT AND DOWNSTREAM SIGNALING 
 PTEN (phosphatase and tensin homology deleted on chromosome 10) is 
one of the most frequently lost tumor suppressors in sporadic cancers. Germline 
mutations of PTEN lead to a variety of rare syndromes, collectively known as the 
PTEN harmatoma tumor syndromes. Essentially, PTEN has dual protein and lipid 
phosphatase activity, the latter is important for its tumor suppressor property [7].  
 Mechanistically, receptor tyrosine kinases (RTKs) activate 
phosphatidylinositol 3-kinase (PI3K) upon stimulation by growth factors e.g. 
insulin [8, 9]. Subsequently, PI3K generates phosphatidylinositol-3,4,5-
trisphosphate (PIP3) from phosphatidylinositol-4,5 bisphosphate (PIP2) [10, 11]. 
Generally, PTEN exerts its tumor suppressor property by opposing the reaction 
catalyzed by PI3K [12]. PIP3 is critical in initiating the signaling cascade by 
recruiting both the Akt and phosphoinositide-dependent kinase-1 (PDK1) to the 
plasma membrane. The close proximity of Akt and PDK1 at the membrane 
facilitates the phosphorylation of Akt on T309 of the activation segment by PDK1 
[8, 9]. However, the full activation of Akt relies on rapamycin-insensitive 
mammalian target of rapamycin complex 2 (mTORC2) which consists of mLST8-
deptor-mSIN1-rictor-mTOR [13]) to phosphorylate Akt on S473 of the 
hydrophobic motif [14]. The reaction is reversed by the PH domain leucine-rich 
repeat protein phosphatase (PHLPP) [15]. The fully activated Akt phosphorylates 
directly multisites of TSC2 (tuberin), a tumor suppressor that forms a 
heterodimeric complex with TSC1 (hamartin) [16, 17]. Functionally, TCS2 is a 
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GTPase-activating protein that associates with TSC1 to inactivate the small G-
protein Rheb [16, 17]. Phosphorylation of TSC2 by Akt inhibits the GAP activity 
of TSC2 toward Rheb and thereby activates mTORC1 (consists of mLST8-deptor-
raptor-mTOR [13]), resulting in downstream signaling cascade [16, 17]. 
Alternatively, Akt can also activate mTORC1 by phosphorylating 40-kDa proline-
rich Akt-substrate (PRAS40), thereby relieving the PRAS40-mediated inhibition of 
mTORC1 [16, 17]. An overview of the PI3K/PTEN/Akt signaling and its 
downstream targets is represented in Fig.2.1.    
 
Fig. 2.1 PTEN/PI3K/Akt signaling pathway. Detailed illustration of the 
PTEN/PI3K/Akt signaling is provided in the text. Solid lines indicate direct 
interactions (activation/inhibition) between the signaling molecules and dotted line 
indicates a possible interaction via unknown mechanism.  Reprinted from Cell, 129, 
Manning and Cantley, AKT/PKB Signaling: Navigating Downstream, page 1261, 




 Activated mTORC1 phosphorylates its substrates, S6 kinase 1 (S6K1) and 
eukaryotic translation initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), the 
key regulators in protein translational machinery. S6K1 promotes protein 
translation by phosphorylating or binding to multiple proteins, which are 
collectively involved in translation, initiation and elongation [16]. Besides, the 
transcriptional activity of the RNA polymerase I (RNAPI) is also controlled by 
mTORC1 through S6K1. In addition to protein translation, S6K can also 
phosphorylate serine residues on insulin receptor substrate 1(IRS1), which targets 
IRS1 for degradation, thereby serving as a negative feedback mechanism to 
attenuate the PI3K/Akt signaling [16].  
 On the other hand, the phosphorylated 4E-BP1 dissociates from eIF4E and 
allows eIF4E to recruit the eIF4G to the 5'-cap of particular mRNAs to initiate 
protein translation [18]. Specifically, some mRNAs of electron transport system are 
translationally upregulated in dietary restriction (DR) dependent extension in 
lifespan, suggesting that the translation mediated by 4E-BP1 is rather specific. 
Interestingly, the preferential translation of certain mRNAs is distinguished based 
on the structural properties of the 5' untranslated regions (5'UTRs). For instance, 
complex I and complex IV mRNAs have lesser/weaker secondary structure and 
lower GC content as well as shorter 5'UTRs. These characteristics confer higher 
folding free energies of 5′UTRs and therefore favour the translation of those 
particular mRNAs [19]. Besides 5'UTRs, 4E-BP1 can modulate the translation of a 
different subset of specific genes through the interactions with eIF4E and eIF4G 
[20]. Notably, the translational machinery is further complicated by the discovery 
of the pumilio family (PUF) proteins. Functionally, PUFs associate with 3'UTRs of 
mRNAs, controlling the stability of these mRNAs and act as a repressor of 
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translation [21]. As each PUF protein has distinct target mRNAs, the 4E-BP1-PUF 
proteins interaction may add another layer of specificity in determining the mRNAs 
that are translationally regulated by 4E-BP1.  
 Although both S6K and 4E-BP1 are involved in protein translation, they act 
differently in tumorigenesis. While S6K is dispensable for cancer formation, 4E-
BP1 acts as a key effector to integrate oncogenic signalings (e.g. Akt and Erk) for 
tumorigenesis [22-24]. Thus, 4E-BP1 appears to be a more attractive target in anti-















2.1.1 PI3K/Akt signaling and cancers 
 Abnormalities in the PI3K/Akt signaling are implicated in human 
malignancies. This is due to the fact that the PI3K/Akt signaling pathway bifurcates 
at many signaling nodes thereby resulting in diverse functional consequences. For 
instance, PI3K/Akt promotes cell survival by inactivating pro-apoptotic molecules 
such as BAD, procaspase-9 and Forkhead (FKHR) transcription factors [25]. In 
addition, the anti-apoptotic effect of PI3K/Akt has been found to be dependent on 
mitochondrial hexokinase, indicating the coupling of metabolism to cell survival 
[26, 27]. 
 Apart from promoting cell survival, PI3K/Akt signaling stimulates the 
proliferation of cell via mTOR-mediated protein translation pathway as mentioned 
above. Besides, Akt inactivates cyclin-dependent kinase inhibitors and lead to 
increase in cellular proliferation [25]. Furthermore, Akt could also promote 
angiogenesis via vascular endothelial growth factor and hypoxia inducible factor-
1α [25]. Bioenergetically, Akt enhances metabolism to provide more ATP and 
building blocks to support growth and proliferation [28, 29]. In addition, PI3K/Akt 
signaling also plays a key role in tumor metastasis [30]. Taken together, the 
pleiotropic effects of PI3K/Akt contributes to multiple hallmarks of cancer in 





Fig. 2.1.1 Hallmarks of cancer. PI3K/Akt involved directly or indirectly in most 
of the signalings in the hallmarks of cancer as detailed in the text. Diagram shows 
ten hallmarks of cancer and possible therapeutic interventions. Reprinted from Cell, 
144, Douglas Hanahan and Robert A. Weinberg, Hallmarks of Cancer: The Next 

























2.1.2. Clinical management of PI3K/Akt-mutated cancers 
 As discussed above, activated PI3K/Akt signaling promotes many 
processes critical to the malignant phenotype. Akt, is therefore portrayed as an 
attractive therapeutic target for cancer. Indeed, the phase I clinical trial of Akt 
inhibitor MK-2206 showed to be well-tolerated at biologically active doses that 
inhibit Akt signaling [31]. However, targeting PI3K/Akt signaling in anti-cancer 
intervention posseses several major challenges. For instance, most solid tumours do 
not have single, dominant oncogenic abnormalities that can be targeted with high 
efficiency [25]. This explained the inhibition of both PI3K/Akt and Erk pathways is 
substantially more effective than inhibition of either pathway alone. Secondly, the 
presence of feedback loop in PI3K/Akt pathway via S6K as discussed above had 
mitigated the efficacy of PI3K/Akt inhibitors. Lastly, similar to other anti-cancer 
drugs, the adaptations of tumors to the treatments pose a critical threat to the 
PI3K/Akt inhibitors in cancer therapy [32]. Therefore, identification of oncogenic 
signalings in the tumors prior to combinatorial interventions accompanied with 
complementary therapies to overcome resistance of cancers may further improve 








2.2 TUMOR METABOLISM 
2.2.1 Glucose Metabolism 
 Interest in tumor metabolism has been revived over the past decade in 
cancer research. Undoubtedly, the early observation by Otto Warburg nearly 80 
years ago provides the fundamental concept for this area of research. However, 
advances in cancer biology, particularly the oncogene revolution has alluded that 
the observation of the "Warburg effect" alone is inadequate to explain 
tumorigenesis. It is now evident that most if not all the signalings from oncogenes 
or tumor microenvironment (e.g. hypoxia) converge on energy metabolism to 
support tumor growth and survival, making this topic once again one of the most 
intense fields of study in cancer research. 
 In the early 19th century, the German scientist Otto Heinrich Warburg 
observed that cancer cells have a high propensity to ferment glucose to lactic acid 
even in the presence of oxygen, a phenomenon termed aerobic glycolysis or the 
"Warburg effect" [1]. He concluded that the Warburg effect in cancer metabolism 
is due to the irreversible injury to respiration [6, 33]. To compensate for the lower 
amount of ATP produced via glycolysis, cancers acquired elevated rate of 
glycolysis [33, 34]. In fact, a number of glycolytic enzymes, particularly 
mitochindria-bound hexokinase isoform II (mtHK II) are often found up-regulated 
in cancers [35, 36]. Essentially, mtHK II has a pivotal role in aerobic glycolysis 
due to: a) mtHK II has preferential access to ATP synthesized from mitochondria 
[37] and b) it is protected from product inhibition by gluocose-6-phosphate  [34, 35] 
(Fig.2.1.2B). Together, mtHK II ensures a higher rate of glucose flux in cancer 
cells [38]. In fact, the “sugar rush” phenomenon in cancers has been exploited 
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clinically for the detection of tumors by the 18FDG-Positron Emission Tomography 
(18FDG-PET) [2]. The mechanism underlying the detection of 18FDG-PET is 
shown in Fig.2.1.2A. 
 
    
 
Fig. 2.1.2 Clinical application and mechanism of Warburg effect. A) The 
18FDG-Positron Emission Tomography (18FDG-PET) scan is based on the use of 
radio-labelled 2-18fluorodeoxy-D-glucose (18FDG) that is taken up by cancer cells 
and phosphorylated by the enzyme hexokinase (frequently mitochondrial-bound 
hexokinase II) to yield 2-18fluorodeoxy-D-glucose-6-phosphate (18FDG-6-P) that is 
not further metabolized and accumulated in the tumor. B) A schematic diagram of 
mitochondrial-bound hexokinase II (mtHK II) to show the interaction between HK 
II and voltage-dependent anion channel (VDAC) on the mitochondrial outer 
membrane (MOM). mtHK II gains preferred access to ATP synthesized by the 
ATP synthasome on the mitochondrial inner membrane (MIM). The structural 
integrity of this entire network is essential for the survival of those cancer cells that 
exhibit the “Warburg” effect. Besides providing support for tumor growth, the 
mtHKII-VDAC structure also has anti-apoptotic effect. Reprinted from Journal of 
Bioenergetics and Biomembranes, 39, Peter L. Pedersen, Warburg, me and 
Hexokinase 2: Multiple discoveries of key molecular events underlying one of 
cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis 








 The high dependence of cancer cells on aerobic glycolysis has exposed their 
Achilles heels in anti-cancer interventions. The non-metabolizable glucose 
analogue 2-deoxy-D-glucose (2-DG) inhibits glycolysis and therefore showed great 
potential in clinical trial [39]. In addition, a plant stress hormone, methyl jasmonate 
was reported to have selective anti-cancer property by detaching mitochondria-
bound HK from voltage-dependent anion channel (VDAC) to induce 
mitochondrial-mediated apoptosis [40]. Similarly, the hexokinase inhibitor, 3-
bromopyruvate has been shown to exert potent selective anti-cancer effect [3, 41]. 
 Bioenergetically, the amount of ATP generated per glucose molecule 
consumed from glycolysis is far less efficient as compared to from oxidative 
phosphorylation (OXPHOS, 2 ATP from glycolysis vs. 36 ATP from OXPHOS). 
Nevertheless, it is now recognized that aerobic glycolysis provides more than 
energy alone. For instance, the up-regulation of a less efficient isoform of pyruvate 
kinase M2 (PKM2) in cancer cells allows intermediates of glycolysis to accumulate 
for biosynthesis of macromolecules to support cell growth and proliferation [42]. 
Likewise, NADPH generated from the pentose-phosphate pathway (PPP) fuels the 
synthesis of building blocks, namely nucleic acids and lipids and acts as a critical 
antioxidant to quench the reactive oxygen species through the biosynthesis of 







2.2.2. Mitochondrial biology in cancer 
 Despite the fact that aerobic glycolysis is well-known in many cancers, the 
cause of this bizarre metabolic alteration remains elusive. Several mechanisms 
have been proposed to contribute to the Warburg effect. These include: a) 
irreversible mitochondrial defects, b) adaptation to hypoxia, c) oncogenic signals, 
and d) abnormal expression of metabolic enzymes [45]. However, studies from our 
group [46] and others [47-49] suggested that the concept of permanent impairment 
of respiration causing aerobic glycolysis in cancers is too simplistic. Rather, 
OXPHOS may be dynamically regulated by oncogenes throughout the course of 
carcinogenesis [50]. In fact, a previous study showed that Akt stimulates aerobic 
glycolysis without any deleterious effect on respiration [5]; this has challenged the 
view of irreversible injury of respiration causing aerobic glycolysis in cancers [6]. 
Nonetheless, it is important to note that the signaling that stimulates respiration 
may have inverse effect on glycolysis and vice-versa. For instance, the tumor 
suppressor p53 reverses Warburg effect by promoting respiration (via glutaminase 
2 [51] and SCO2 [52]) and inhibiting glycoysis (via TIGAR [53], PGM, glucose 
transporters) [44] (Fig. 2.2.1). In addition, impairment in respiration activates Akt 
[54] suggesting a possible cross-talk between respiration/glycolysis and signaling 
pathways. 
 While more evidence is required to establish the cause(s) of the Warburg 
effect in cancers, the role of mitochondrial biology in tumorigenesis is evident. 
Particularly, the mutations in isocitrate dehydrogenase 1/2 (IDH1/2) have been 
found in many cancers [55]. Both IDH1 and 2 are highly homologous; the former is 
localized in the cytoplasm and peroxisomes, while the latter is a mitochondrial 
protein involved in the tricarboxylic cycle (TCA) [55]. Interestingly, instead of 
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generating the reducing equivalents NADH or NADPH, the mutated IDH1/2 carry 
out the novel reaction which uses the reducing equivalents and produces the "onco-
metabolite" 2-hydroxyglutarate (2-HG) from α-ketoglutarate (α-KG) [56]. As a 
result, cells harbour mutated IDH1/2 have higher oxidative stress [55]. Moreover, 
2-HG is involved in the regulations of epigenetic (DNA or histone modifications) 
and HIF signaling to promote tumorigenesis [55].  
 Similarly, TCA enzymes such as succinate dehydrogenase (SDH) (one of 
the components in electron transport system) and fumarate hydratase (FH) have 
been discovered to be tumor suppressors [57]. The dysfunctional SDH and FH 
cause the accumulation of succinate and fumarate. Both chemically similar 
products leak out from mitochondria to cytosol and inhibit a family of prolyl 
hydroxylase enzymes (PHs) [57]. This prevents the hydroxylation of HIF thereby 
inhibits the degradation of HIF leading to a phenomenon known as pseudo-hypoxia 
[58]. As a transcription factor in hypoxia, HIF up-regulates glycolysis, promotes 
angiogenesis and other signaling events that are critical for tumorigenesis [58]. 
Moreover, PHDs can also be inhibited by reactive oxygen species (ROS) generated 
from the defective electron transport system resulting in the stabilization of HIF 
[59]. Furthermore, the carnitine palmitoyltransferase-1C, an enzyme in β-oxidation 
has been found to be an oncogene that promotes tumor survival in response to 
metabolic stress [60, 61]. Taken together, besides the prevailing viewpoint on the 
importance of aerobic glycolysis in cancer, mitochondrial metabolism has emerged 





2.2.2 glutamine metabolism 
 While intensive research is still progressing to unveil the therapeutic 
opportunities of targeting aerobic glycolysis in cancers, several research groups 
have made revolutionary discoveries on the altered glutamine metabolism in 
cancers [62-64]. In fact, as compared to other amino acids, glutamine has long been 
recognized to play a critical role to support tumor growth [65-67]. Recent interest 
is due to the discovery of the interplay of oncogenes (eg. Myc) with glutamine 
metabolism in cancers [68, 69].  
 Being the most abundant non-essential amino acid (NEAA) [70], glutamine 
has pleiotropic effects on cell proliferation. Particularly, glutamine is the obligate 
nitrogen donor for nucleotide synthesis; several major steps in purine and 
pyrimidine synthesis require glutamine as a source of nitrogen [71, 72]. Besides, 
the nitrogen from glutamine is also required in the synthesis of other NEAA 
(alanine, serine, aspartate, and ornithine) [71, 72]. Furthermore, glutamine is 
essential for tumor to thrive in an hypoxic environment. For instance, pyruvate is 
diverted from the TCA to produce lactate in hypoxia as a results of the inhibition of 
pyruvate dehydrogenase (PDH) by hypoxia-inducible factor-1α (HIF-1α) via PDK1 
[73, 74]. Hypoxic tumor replenishes (via anaplerosis) its truncated TCA 
intermediates from glutamine which enters the cycle via α-ketoglutarate (α-KG) 
[75]. As glutamine is oxidized to succinate through multiple steps in the TCA, 
reducing equivalents (NADH and FADH2) are generated to feed into ETC to 
maintain the mitochondrial membrane potential (MMP) [71, 72]. In addition, 
intermediates generated from the TCA cycle can be used for the synthesis of lipids 
via reverse TCA (from α-KG to citrate) [64, 76] and NADPH (mediated by malic 
enzyme) [64].  
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 Beyond its role in intermediates and redox metabolism, glutamine is 
implicated directly in oncogenic signaling. For instance, glutamine uptake and 
subsequent rapid efflux through the transporter Slc7a5 (LAT1) in exchange for 
essential amino acids (EAA) allows EAA-dependent mTORC1 activation to 
promote cell growth and proliferation [70, 75, 77, 78]. Furthermore, glutamine is 
involved in the rate-limiting step in hexosamine synthesis; the latter is required for 
the modification of proteins or lipids for their participation in signal transduction, 
trafficking/secretion and other processes [71].  
 Taken together, it is becoming clear that metabolic perturbations of cancer 
cells are not passive responses to damaged mitochondria. Rather, they result from 
oncogene(s)- and microenvironment-directed metabolic reprogramming which are 




Fig. 2.2.1 Signalings and their regulation of glucose and glutamine metabolism. 
Glucose metabolism-coupled to ATP production involves glucose uptake, 
glycolysis, tricarboxylic acid cycle (TCA) and lastly oxidative phosphosrylation 
(OXPHOS). Of note, glucose can be used for nucleotides synthesis via pentose-
phosphate pathway. Intermediates of TCA cycle, particularly citrate can be used for 
lipid and amino acids synthesis. Oncogenic signaling of Akt enhances aerobic 
glycolysis partly through HK II-VDAC interaction [79]. Pyruvate kinase M2 
(PKM2) has low affinity to its substrate phosphoenolpyruvate (PEP) and therefore 
favours the accumulation of glycolytic intermediates for biosynthesis. On the other 
hand, p53 exerts it tumor suppresive effect by inhibiting  Tp53-induced glycolysis 
and apoptosis regulator (TIGAR) [53] and phosphoglycerate mutase (PGM), as 
well as enhancing OXPHOS functions by up-regulating synthesis of cytochrome c 
oxidase 2 (SCO2) [52] and glutaminase 2 [51]. Myc up-regulates glutaminase 1 to 
support tumorigenesis [69]. Reprinted from Science, 330, Arnold J. Levine and 
Anna M. Puzio-Kuter, The Control of the Metabolic Switch in Cancers by 
Oncogenes and Tumor Suppressor Genes, 2010, with permission from The 
American Association for the Advancement of Science (License Number: 
3286920019254). 




2.3 REACTIVE OXYGEN SPECIES (ROS) IN CANCER 
BIOLOGY 
 
 Aerobes use oxygen (O2) for efficient production of energy from the 
oxidation of nutrient in mitochondria. O2 functions as a "dumping ground" for 
electrons from the electron transport system (ETS). As the final electron acceptor 
in ETS, O2 is reduced at complex IV (cytochrome c oxidase) to water. The need for 
O2 conceals the fact that it is a toxic mutagenic gas. The toxicity arises from the 
incomplete reduction of O2 to form superoxide free radical (O2•  ̶ ). A free radical is 
defined as any species capable of independent existence (hence the term free) that 
contains one or more unpaired electrons [80]. In this study, we focus on the role of 
reactive oxygen species (ROS) in cancer biology.  
 ROS is the collective term for oxygen radicals, including hydroxyl (OH•) 
and superoxide (O2•  ̶ ) as well as some other non-radical derivatives of oxygen, 
such as hydrogen peroxide (H2O2), that can easily generate free radicals and/or 
cause oxidative damage [81]. Generally, the mitochondrion contributes to 90% of 
total cellular ROS [82]. This is due to the fact that the alternating one-electron 
oxidation-reduction reactions catalyzed in ETS predispose each electron carrier 
(particularly complex I and III) to side reactions with O2 to form O2•  ̶  [83]. 
Thermodynamically, the production of O2•  ̶  is readily generated in vivo owing to 
the fact that: a) reduction potential of O2•  ̶  at physiological condition is high (> 
200mV); a wide range of electron carriers along the ETS are capable of carrying 
out the one-electron reduction of O2 [84], b) The concentration of O2 ([O2]) is 
higher at the membrane than in soluble compartment. Thus, the interaction between 
O2 and the electron carriers present within the membrane is enhanced [85]. O2•  ̶  
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generated within mitochondria is quickly dismutated by mitochondrial superoxide 
dismutase (MnSOD) to form H2O2 [86]. Apparently, H2O2 is more harmful than 
O2•  ̶  as it forms the more reactive hydroxyl radical (OH•) in the presence of metals 
(Fenton reaction, Fig.2.3.1a, [87]) or undergoes homolytic fission in the presence 
of UV light (Fig.2.3.1b) [80].  
 
Fig. 2.3.1 Schematic diagram of the chemistry reactions of superoxide (O2•  ̶  ). 
O2•  ̶  can undergo either (a) Fenton reaction or (b) homolytic fission. 
 While the detrimental effect of ROS on other pathological conditions are 
controversial, the implication of ROS in tumorigenesis is evident [88-90]. In fact, 
ROS attack any cellular molecule. However, with respect to cancer, DNA is 
considered the most important target. Particularly, the modified lipids and proteins 
can be removed by normal turnover of the molecules, damaged DNA must be 
repaired. Notably, oxidative DNA damage caused by ROS such as OH• generates 
multiple mutagenic purine, pyrimidine and deoxyribose oxidation products [88]. Of 
note, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8OHdG) is one of the most abundant 
DNA lesions, often used as the biomarker for oxidative DNA damage [91]. Besides, 
8OHdG is also the most mutagenic DNA lesion, resulting in G → T transversions 
which are frequently found in critical genes such as oncogenes or tumor suppressor 
genes [77, 88]. Indeed, studies have shown that the mutagenic effect of ROS is 
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involved in all stages in tumorigenesis from initiation, progression, to promotion 
[77, 88, 91, 92].  
 In addition to genetic alterations, ROS itself is directly involved in 
oncogenic signaling. For instance, the "onco-ROS", O2•  ̶  has been shown to have 
anti-apoptotic property in tumor by creating a pro-oxidant milieu [90]. Indeed, a 
recent study suggests that O2•  ̶ can promote cytosolic Akt hyperactivation [93]. 
Besides PI3K/PTEN/Akt signaling, ROS is implicated in MAPK, PKC, protein 
tyrosine phosphatases and NF-κB signalings to promote tumor proliferation, 
invasion as well as survival [77]. 
 In view of the detrimental effects of ROS, one might ponder why nature 
preserves this feature. In fact, free radicals are involved in most life processes, 
including human diseases and evolution -- "you cannot escape them, nor should 
you wish to" [80, 89]. From the evolutionary point of view, free radicals are 
essential to keep us survive from infection until we reached post-reproductive years. 
This is particularly relevant to our ancestors, who lived in poor hygienic 
environment. Obviously, it does not mean to keep us from getting age-related 
diseases (e.g. cancers etc.) since our ancestors had shorter lifespan as compared to 
us. Only now the mean lifespan has dramatically increased and we are facing the 
new challenge from the by-product of evolution. Fortunately, the hitherto 
knowledge in redox biology has widen our perspective in biomedical research and 




CHAPTER 3  PTEN/AKT SIGNALING CONTROLS 
MITOCHONDRIAL RESPIRATORY CAPACITY 
THROUGH 4E-BP1 
3.1 INTRODUCTION 
 PTEN (phosphatase and tensin homology deleted on chromosome 10) is one 
the tumor suppressors frequently lost in cancers [94, 95]. It has both protein and 
lipid phosphatase activities; the latter is associated with tumor suppression [96, 97]. 
By dephosphorylating phosphatidylinositol-3,4,5-trisphosphate (PIP3), PTEN 
prevents the membrane recruitment and activation of Akt which promotes cell 
survival, proliferation, growth and glycolysis [12, 16]. The ability of Akt in 
stimulating cell proliferation is best illustrated in Cowden and other PTEN 
hamartoma tumor syndromes [98]. The benign nature of these tumors could be due 
to the fact that neither PTEN nor Akt alone is sufficient for the cell to become 
cancerous [99, 100]. The signaling downstream of Akt is integrated by mTOR 
(mammalian target of rapamycin) and transduced to ribosomal protein kinase S6 
kinase (S6K) and the eukaryotic translation initiation factor 4E (eIF4E)-binding 
proteins (4E-BP1, 2 and 3) to regulate protein translation [101]. 4E-BP1 is a 
repressor of 5’cap-dependent mRNA translation and it is inactivated upon 
phosphorylation by mTORC1. The phosphorylated 4E-BP1 is then released from 
the eukaryotic initiation factor 4E (eIF4E) which subsequently binds eIF4G to 
begin protein translation [18]. The regulation and mechanistic action of 4E-BP1 is 
depicted in Fig. 3.1. Furthermore, 4E-BP1 has been shown to be the key effector of 
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oncogenic activation of the Akt and ERK signaling pathways that integrate their 
function in tumors [22]. It correlates with the clinical findings that expression of 
high level of phosphorylated 4E-BP1 is associated with poor prognosis in several 
types of tumor, independent of the alteration of upstream oncogenic signaling [102]. 
                           
 
Fig. 3.1 The regulation and mechanistic action of 4E-BP1 on protein 
translation. Upon phosphorylated by mTOR, 4E-BP1 detaches from the binding to 
the initiation factor (IF). The unbound IF is active and able to initiate the 









 While the activation of Akt by defective respiration in cancer cells has been 
shown to stimulate aerobic glycolysis [5, 54], the action of Akt on the 
mitochondrial respiration in cell transformation remains largely unknown. In this 
study, MEFWT and MEFPTEN-/- are used as a model to examine if the PTEN/Akt 
pathway has an effect on oxidative metabolism in normal and transformed cells. 
We compared a number of mitochondrial parameters and found that the MEFPTEN-/- 
with hyper-activated Akt exhibited higher enzyme activities and protein 
expressions of all respiratory complexes.  Pre-treatment of MEFPTEN-/- with 
LY294002 (LY), an inhibitor of PI3K and mTOR [103] and Akt inhibitor IV 
decreased (a) the phosphorylation of Akt at both Ser473 and Thr308, (b) the 
phosphorylation of 4E-BP1 at Thr37/46 and (c) the expressions of RC I, III and IV.  
We also measured the mRNAs of the same subunits of the RCs detected in Western 
blots and the protein expressions of the peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC-1α), the nuclear respiratory factor 1 (NRF-1) and 
mitochondrial transcription factor (mtTFA) and showed that the regulation of 
mitochondrial function by Akt is probably not dependent on transcription.  In 
conclusion, the higher proliferation in MEFPTEN-/- was accompanied by increased 
mitochondrial respiratory capacity.  The protein expressions of the RCs in 
MEFPTEN-/- are attenuated by LY294002 and Akt inhibitor IV but are increased in 
MEFWT by siRNA targeting PTEN or 4E-BP1, suggesting a regulation of 
mitochondrial respiratory activities by the PTEN/Akt/mTOR pathway through 4E-




3.2 RESULTS  
3.2.1 Characterization of MEF PTEN-/-  
 
 We first confirmed the PTEN knockout phenotype in MEFPTEN-/- by 
immunoblotting the protein expressions of PTEN, total and phospho-Akts in the 
whole cell lysate. The absence of PTEN causing Akt hyperactivation was evident 
by the higher expressions of p-Ser473Akt and p-Thr308Akt without a significant 
change in the total Akt (Fig. 3.2.1A).  In the absence of PTEN, a significantly 
higher rate of proliferation was observed in MEFPTEN-/- from day 1 to 4 (Fig. 3.2.1B) 
with a doubling time of 22hr and 16hr, respectively, for MEFWT and MEFPTEN-/- 




Fig. 3.2.1 Characterization of MEFPTEN-/-. (A) Western blot analyses of PTEN, 
Akt, p-Ser473Akt and p-Thr308Akt Immunoblotting of PTEN, Akt, p-Ser473Akt 
and p-Thr308Akt was carried out on whole cell lysates of MEFWT and MEFPTEN-/-. 
The loss of PTEN in MEFPTEN-/- resulted in hyperactivation of Akt on both 
phosphorylation sites without affecting the expression of total Akt. The respective 
loading controls of a-tubulin were included. Western blots presented are 
representative of 3 independent experiments. (B) Rate of cell proliferation. This 
was measured by the trypan-blue exclusion assay. The MEFPTEN-/- has a 
significantly higher rate of proliferation compared to MEFWT from days 1–4 of 
culture. # p < 0.005 for n = 3. 
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3.2.2 Oxidative phenotype in MEF PTEN-/-   
ATP biosynthesis - The overall function of mitochondria in energy production was 
measured by the rate of ATP biosynthesis in isolated intact mitochondria upon the 
addition of respiratory substrates.  As shown in Fig. 3.2.2A, the rate of ATP 
biosynthesis from the oxidation of malate/glutamate for respiratory complex I 
(RCI), succinate for RCII and TMPD/ascorbate for RCIV was significantly higher 
in MEFPTEN-/- compared to the MEFWT.  
Mitochondrial Membrane potential (MMP) - The generation of mitochondrial 
membrane potential is often used as an indicator to assess mitochondrial respiratory 
function. We measured the MMP of intact mitochondria using the JC-1 dye with 
serial addition of substrates and inhibitors. The uptake of JC-1, a cationic dye, 
depends essentially on the MMP. The oxidation of respiratory substrates such as 
malate/glutamate and succinate added to mitochondria induced the generation of 
MMP, resulting in an increased entry of JC-1 monomers which exhibited a green 
fluorescence. With enhanced accumulation, the monomers combined to form J-
aggregates which showed a red fluorescence. The ratio of red:green fluorescence 
measured the magnitude of the MMP.  The MMP induced by malate/glutamate and 
succinate was higher in the MEFPTEN-/-  compared to MEFWT as shown in Fig. 
3.2.2B.  Inhibition of RCI by rotenone and of RCII by malonate confirmed the 





Fig. 3.2.2 Biosynthesis of ATP and Mitochondrial membrane potential (MMP) 
in MEFWT and MEFPTEN-/-. (A)  The biosynthesis of ATP was carried out in 
isolated mitochondria which showed a higher rate of ATP generation in MEFPTEN-/- 
compared to MEFWT. The respiratory substrates (± inhibitor) were 5 mM each of 
malate/ glutamate (M/G), 10 mM succinate + 5 μM rotenone, and 1 mM TMPD 
and 5 mM ascorbate in the presence of 2 μg/ml antimycin A. * p < 0.05, # p < 0.005 
for n = 3. (B) The cationic dye, JC-1was used to monitor MMP. JC-1 monomers 
(green fluorescence) form J aggregates (red fluorescence) in the matrix upon 
energization by added respiratory substrates namely malate/glutamate (M/G, 5 mM 
each) and succinate (10 mM). Rotenone (5 μM) and malonate (10 mM), inhibitors 
of RCI and II, respectively, decreased the MMP as reflected by an attenuation of 
the ratio of red:green fluorescence. Mitochondrial protein used was 0.5 mg. Data 





Fig. 3.2.2 (C) The oxygen consumption of MEFWT and MEFPTEN-/-. The NetR/E 
(where R = Routine and E =maximal electron transport system capacity) was 
obtained as described under ‘‘Experimental procedures’’ using an Oxygraph 2k 
(Oroboros). A higher NetR/E was observed in MEFPTEN-/- compared to MEFWT as 
shown in a representative set of data. On the other hand, Leak/E was always lower 
in MEFPTEN-/-. A significantly higher in NetR/E showed that the electron transport 
system was more efficient in driving ATP synthesis in MEFPTEN-/- compared to 






Figure 3.2.2 (D) Enzyme activities of the respiratory complexes (RCs). These 
were expressed in nmol/min/mg protein. They were measured as described in the 
‘‘Experimental procedures’’. Ratios of RC III/I, IV/I and IV/III are also. * p < 0.05,  










Figure 3.2.2 (E) Western blot analyses of respiratory complexes (RCs). Whole 
cell lysates of MEFWT and MEFPTEN-/- were probed with a cocktail containing 
antibodies against various subunits of the five RCs as described in the text. 
Quantification of the bands by the ImageJ software showed % increase in protein 
expressions of RCs in MEFPTEN-/- relative to MEFWT. A higher degree of increase 
in RCI, III and IV, as compared to RCII and V was apparent. p values were 




Figure 3.2.2  (F) Activities of GDH and TCA cycle enzymes. Glutamate 
dehydrogenase (GDH), malate dehydrogenase (MDH) and citrate synthase (CS) 
were measured in freeze-thawed mitochondrial extracts as described in [46]. # p < 




Respiratory Flux - To investigate the effect of PTEN/Akt on mitochondrial 
function, oxygen consumption was measured with intact cells in normal culture 
medium. As compared to isolated mitochondria, the intact cell analysis allowed an 
integration of regulatory events by which cytoplasmic and nuclear factors 
influenced mitochondrial function. Net R/E (where R = Routine and E = ETS) 
combined basal oxygen consumption (Routine), oligomycin-inhibited respiration 
(Leak) and maximal capacity of electron transport system (E) to provide a 
parameter R/E which measured the proportion of respiratory capacity coupled to 
oxidative phosphorylation. As shown in a representative set of data for MEFPTEN-/- 
and MEFWT (Fig. 3.2.2C), the former had higher Net Routine/E, which inferred that 
a higher proportion of oxygen consumption of the electron transport system was 
coupled to ATP synthesis.  This could be contributed by a lower degree of leak 
respiration, expressed as Leak/ETS as shown in Fig. 3.2.2C, which was obtained 
from three independent experiments.  
 
Activities and protein expressions of respiratory complexes - The higher MMP and 
rate of ATP biosynthesis in MEFPTEN-/- observed above suggested a possible 
increase in the coupling of the electron transport system to the phosphorylation of 
ADP.  This was reflected in the data of respiratory flux above. Indeed, extracts of 
mitochondria isolated from MEFPTEN-/- showed higher activities of all five 
respiratory complexes compared to the MEFWT (Fig. 3.2.2D). Interestingly, the 
ratios of RC III/I, IV/I, and IV/III in the MEFPTEN-/- were similar in magnitude to 
those in the MEFWT (Fig 3.2.2D, inset). This observation alluded to a coordinated 
regulation of these RCs via transcription, translation and/or post-translation. At the 
protein level, we observed higher expressions of all five RCs in the MEFPTEN-/- 
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compared to the MEFWT (Fig. 3.2.2E).  Quantification of the bands using the 
ImageJ software showed a significant difference based on triplicate measurements 
and a higher magnitude of increase in RCI, III and IV compared to RCII and V (Fig. 
3.2.2E).  
Tricarboxylic acid (TCA) cycle enzymes – To sustain a higher MMP and rate of 
ATP biosynthesis, more reducing equivalents must be fed into the electron 
transport system from the TCA cycle.  We found the activities of glutamate 
dehydrogenase (GDH) and malate dehydrogenase (MDH), two NAD-linked 
enzymes as well as citrate synthase (CS), a  mitochondrial marker enzyme, were 
significantly higher in the MEFPTEN-/- as compared to the MEFWT (Fig 3.2.2F).  
3.2.3 Enhanced mitochondrial function in MEFPTEN-/-  
(a) Akt hyperactivation 
A significantly higher protein expression of all RCs was found in MEFWT with 
siRNA knockdown of PTEN (Fig. 3.2.3A and inset).  The PTEN-knockdown cells 
exhibited higher Net R/E with lower Leak/E (Fig 3.2.3B), suggesting that PTEN 
aberration could be responsible for the enhanced coupling between oxidation and 
phosphorylation in mitochondria isolated from MEFPTEN-/- (shown previously as 
NetR/E in Fig 3.2.2C).  To further explore if the higher mitochondrial respiration in 
MEFPTEN-/- was attributed to hyperactivated Akt, inhibition of the PI3K/Akt 
signaling pathway was attempted with LY294002, which is known to act on PI3K 
and mTOR [103-105] and Akt Inhibitor IV, an ATP-competitive inhibitor of Akt 
autokinase activity [106].  Both inhibitors reduced the phosphorylation at Ser473 
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and Thr308 of Akt without affecting the total Akt (Fig. 3.2.4A and 3.2.4B). The 
reduction in Akt phosphorylation by these two inhibitors correlated with (a) 
decreased enzyme activities of all four electron-transport complexes (I to IV) in 
MEFPTEN-/- (Table 3.1) and (b) repression of the protein expressions of RCI, III, and 
IV (these are involved in proton pumping) in MEFPTEN-/- (Fig 3.2.4C and 3.2.4D). 
The protein expressions of RCII and V were either not or minimally affected.  
  % inhibition of RC activities 
LY 294002 Akt Inhibitor IV 
RC I 14.9 ± 0.87# 66.5 ± 6.99# 
RC II 33.7 ± 9.18** 38.6 ± 7.89** 
RC III 26.8 ± 8.25** 38.1 ± 1.01# 
RC IV 21.3 ± 4.41** 42.9 ± 6.06# 
 
Table 3.1 Inhibition of enzyme activities of respiratory complexes. Activities of 
respiratory complexes I to IV were inhibited by LY294002 (inhibitor of PI3K and 
mTOR) and Akt inhibitor IV. Values are expressed as % inhibition compared to 










Fig. 3.2.3 siRNA-mediated silencing of PTEN in MEFWT. (A) Western blot 
analyses of respiratory complexes. The protein expressions of all five RCs were 
significantly up-regulated by si-RNA of PTEN. A higher degree of increase in RCI, 
III and IV, as compared to RCII and V was apparent (inset). Western blots 
presented are representative of 3 independent experiments. (B) Oxygen 
consumption. si-RNA of PTEN was accompanied by an increase in the net oxygen 
consumption expressed as NetR/E and a decreased Leak/E when compared to 





   
Fig. 3.2.4 Effects of LY294002 and Akt inhibitor IV on MEFPTEN-/-. MEFPTEN-/- 
were exposed to 25 mM LY294002 for 4 h or 1 mM Akt inhibitor IV for 8 h. (A, B) 
Western blot analyses of p-Ser473Akt, p-Thr308Akt and total Akt. Expressions of p-
Ser473Akt, p-Thr308Akt were compromised by LY and Akt inhibitor IV, 
respectively, while total Akt remained relatively unchanged. (C, D) Western blots 
of respiratory complexes. Protein expressions of respiratory complexes I, III and IV 
were down regulated by LY and Akt inhibitor IV. Those of RCII and RCV 









(b) Regulation of gene transcription   
The peroxisomal proliferator activated receptor γ coactivator-1α (PGC-1α) and its 
downstream targets: nuclear respiratory factor-1 (NRF-1) and mitochondrial DNA 
transcription factor A (mtTFA) are all known to enhance respiratory function by 
acting on several nuclear genes encoding subunits of the respiratory complexes 
[107, 108]. The level of these proteins could provide some indication if 
transcriptional regulation played a role in the Akt-mediated up-regulation of 
mitochondrial activities observed in MEFPTEN-/-.  No significant difference was 
observed in their protein expressions (Fig 3.2.5A and inset). Similarly the 
expressions of mRNAs of the five subunits of respiratory RCs used in our Western 
blot analyses were not significantly different between MEFPTEN-/- and MEFWT (Fig 
3.2.5B and inset).  Together, these sets of data suggested that the increased 









Fig. 3.2.5 Transcriptional Regulation of RCs. (A) Western blots of 
mitochondrial transcription factors. The protein expressions of peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α),  nuclear 
respiratory factor-1 (NRF-1) and mitochondrial DNA transcription factor A 
(mtTFA) were measured in MEFWT and MEFPTEN-/-. Quantitative analysis showed 
no significant difference between the two. (B) Measurement of mRNA by real-time 
PCR. The mRNAs of the five subunits RCs used in our Western blot analysis were 
not significantly different in MEFPTEN-/- and MEFWT with p values shown in the 





(c) 5’ cap-dependent protein translation 
 We next explored if the Akt-mediated mitochondrial function was regulated 
by protein translation.  As mentioned previously, 4E-BP1 has a central role in 
converging upstream signals to protein translation [22, 102]. MEFPTEN-/- had a 
lower 4E-BP1 (Fig. 3.2.6A) and a higher proportion of p-Thr37/464E-BP1 relative to 
total 4E-BP1 when compared to MEFWT (Fig 3.2.6A, inset).  The mRNA levels of 
4E-BP1 in the two cell types were not significantly different (p = 0.148) as shown 
in Fig 3.2.6B. In addition, the repression of activities and expressions of the RCs 
by LY294002 and Akt inhibitor IV could also be mediated by 4E-BP1 as 
incubation with LY294001 resulted in a band shift downwards in total and p-4E-
BP1 (shown by arrows in Fig. 3.2.6C), a phenomenon which indicates hypo-
phosphorylation [18].  Although there was no band shift with Akt inhibitor IV, 
there was evidence for a more hypo-phosphorylated p-Thr37/46 4E-BP1 and total 
4E-BP1 (shown by arrows of lower bands of greater intensity in Fig. 3.2.6D).  In 
general, hypo-phosphorylation of 4E-BP1 and/or p-Thr37/46 4E-BP1 would lead to a 
lower protein translation which was evident in RC I, III and IV expressions 
following inhibition by LY and Akt inhibitor IV (Figs. 3.2.4C and 3.2.4D). Gene 
silencing of 4E-BP1 in MEFWT and MEFPTEN-/- up-regulated the expressions of all 
RCs (Fig 3.2.6E and 3.2.6F. respectively). The fact that this was also observed in 
MEFPTEN-/- suggested that there was residual 4E-BP1 in these cells which was 
demonstrated in Fig. 3.2.6A. The higher degree of increase in RC expressions in 
the MEFWT by si-4E-BP1 (Fig. 3.2.6E) could be explained by their higher basal 
4E-BP1 (Fig. 3.2.6A). A number of other assorted (mitochondrial and cytoplamic) 
proteins  were also measured following si-4E-BP1, but their protein expressions 
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Fig 3.2.6  (A)  Protein expressions of 4E-BP1 and p-Thr37/464E-BP1. MEFPTEN-/-
has significantly lower total 4E-BP1 but a higher ratio of phospho- relative to  
total- 4E-BP1 (inset). Western blots presented are representative of 3 independent 





                
 
Fig 3.2.6 (B) mRNA Level of 4E-BP1. The mRNA level of 4E-BP1 was not  





Fig 3.2.6 (C, D) The effect of LY 294002 and Akt inhibitor IV  on  total and 
phosphorylated  4E-BP1. (C) Hypo-phosphorylation of 4E-BP1 and p-Thr37/464E- 
BP1 by LY was observed by downward band shifts in both, as  indicated by arrows. 
(D) Hypo-phosphorylation of p-Thr37/46 4E-BP1 and total 4E-BP1 by Akt inhibitor 
IV (shown as bands of higher density, indicated by arrows) was observed but no 




       
Fig 3.2.6 (E, F) The effect of RNA-silencing of 4E-BP1 on protein expressions 
of RCs in MEFWT and  MEFPTEN-/. Up-regulation of the expressions of all RCs 
was apparent, similar to the effects observed by siRNA of PTEN (Fig. 3.2.3A) and 
the RC profiles in MEFPTEN-/- (Fig. 3.2.2E). Western blots presented are 





Fig 3.2.6  (G) Gene silencing of 4E-BP1 with/without Akt Inhibitor IV on RC 
expressions. RC expressions were significantly higher with Si-4E-BP1 compared 
with untreated controls in MEFWT (* p < 0.05 for all values, n = 3). No difference 
was observed in the presence or absence of Akt inhibitor IV with knockdown of 
4E-BP1 (inset). This showed that in the absence of 4E-BP1, Akt might not be able 
to regulate the expressions of the RCs. The increase protein expressions of RC II 
and IV was less robust as compared to Fig.3.2.6E might be due to different 
efficiency of 4E-BP1 knockdown (data not shown). Western blots presented are 







Fig 3.2.6 (H) Mitochondrial protein relative to total cellular protein. The ratio 
was about three times higher in MEFPTEN-/- compared to MEFWT.  The purity of the 
mitochondrial preparation was confirmed by the use of SOD-1 (Cu-Zn superoxide 
dismutase) and VDAC (voltage dependent anion channel), the cytosolic and 
















(d) Direct control of RC expressions by 4E-BP1 
 To examine if 4E-BP1 exerts control directly downstream of Akt activation, 
we performed gene silencing on 4E-BP1 in MEFWT followed by the inhibition with 
Akt inhibitor IV. As shown in Fig 3.2.6G, si-RNA of 4E-BP1 up-regulated all the 
RC expressions in the absence or presence of Akt inhibitor IV (Lanes 2 and 3) as 
compared to untreated controls (Lane 1), indicated by * p < 0.05 and # p < 0.005. In 
other words, with gene silencing of 4E-BP1, the RC expressions were not affected 
by Akt inhibition as shown by p > 0.05 in Fig. 3.2.6G inset. However, when 4E-
BP1 was intact (Lane 4), inhibition of Akt down-regulated RC expressions. This 
positive control showed the efficiency of the Akt inhibitor IV, which has 
previously been demonstrated in MEFPTEN-/- (Fig. 3.2.4D). Together, the results 
suggested that regulation of RC expressions by Akt was dependent on 4E-BP1.  
 
(e) Increased mitochondrial protein relative to total protein  
  In view of the mitochondrial location of the RCs, it was conceivable that 
their up-regulation could contribute to more proteins in this organelle relative to the 
total cellular protein in MEFPTEN-/-. Indeed, we observed a three-fold increase in the 
ratio of mitochondrial protein relative to total cellular protein in MEFPTEN-/-  
compared to MEFWT (Fig. 3.2.6H). The purity of the mitochondrial preparation was 
confirmed by the use of SOD-1 and VDAC, the cytosolic and mitochondrial 





Fig. 3.2.7 The effect of gene silencing of 4E-BP1 on other proteins. There was 
little to no effect on other (cytosolic and mitochondrial) proteins examined (listed 
in Figure 3.2.7) with siRNA on 4E-BP1 in MEFWT (except for Bcl-2 which was 
decreased, p < 0.05 for n = 3). In contrast, there was up-regulation of all respiratory 
complexes as shown in Figure 3.2.6E and 3.2.6F. Western blots presented are 









 The immortalized MEFPTEN-/- [12] provided a cell model to study any 
aberrant metabolism resulting from the oncogenic action of Akt.  Following its 
activation, Akt has been reported to translocate to the mitochondria to act on its 
downstream targets [109].  Thus, there is evidence of a cross-talk between Akt and 
mitochondria. This study explores if Akt hyperactivation has an impact on 
mitochondrial metabolism. It is conceivable that accelerated aerobic glycolysis 
from Akt signaling [5] produces increased pyruvate which is channeled 
concomitantly to lactate and the TCA cycle. The reducing equivalents, NADH and 
FADH2 generated in the mitochondrial matrix are finally oxidized by the active 
electron transport system consisting of up-regulated RCs in MEFPTEN-/-. These 
could contribute to the higher MMP and ATP biosynthesis in MEFPTEN-/- and 
increased oxygen consumption reported in Akt-transfected MEFs [110].  Our study 
also showed consistently higher net routine oxygen consumption in MEFPTEN-/- 
which was reproducible by silencing PTEN in the wild type.  In both instances, the 
lower degree of leak respiration may lead to their greater efficiency in OXPHOS.  
Lower leak is possibly the result of their higher cholesterol content as we had noted 
consistently that 2-3 times more digitonin was required for cell permeabilization of  
MEFPTEN-/-. It has been reported that cholesterol enhances the rigidness of 
mitochondrial membranes leading to a lower leak [111].  In addition, higher 
enzyme activities of the RCs could be another contributing factor.  Of particular 
interest is that the MEFPTEN-/- retain similar relative proportions of activities of RCI, 
III and IV as those present in the wild type which infers that they could be co-
ordinately regulated. These three RCs form supercomplexes known as 
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respirasomes [112, 113] which may subject them to collective regulation.  Our ratio 
of the enzyme activities of 1:2 for RCIII : RCIV is coincidentally similar to that 
deduced in the model of the “respiratory string” which is made up of several 
respirasomes [113].  
 Two inhibitors of the Akt/mTOR pathway were used to examine if the higher 
RC activities and expressions were attributed to hyperactivated Akt from PTEN 
aberration in MEFPTEN-/-. They are LY294002 (LY) which targets both PI3K and 
mTOR [103-105] and Akt inhibitor IV which has previously been reported to block 
Akt autokinase activity [106].  Both inhibitors decreased RC enzyme activities and 
protein expressions of RC I, III, and IV, with little to no change in RCII and RCV, 
an observation which further supports the concept of organization of these three 
proton pumping RCs in supercomplexes of respirasomes discussed above [113].  In 
addition to their co-ordinated regulation, their ease of change could be explained by 
their different values of ∆G of folding energy and the length of the 5’UTRs [19]. 
RC IV with a ∆G of -7Kcal/mol and short 5’UTRs could render it more amendable 
to inhibition and possibly transcription and/or translation in contrast to RCV with a 
∆G of -46Kcal/mol which would be more resistant to change as towards LY and 
Akt inhibitor in this study.  Overall, LY seems to exert a greater influence on the 
band shift of 4E-BP1 as it is an inhibitor of both PI3K and mTOR [103-105]. 
While mTOR phosphorylates 4E-BP1 directly, the phosphorylation of 4E-BP1 by 
PI3K is mediated through Akt (PKB), PKA or PKC which implicates other kinases 
besides Akt in regulating the phosphorylation of 4E-BP1 [114]. Furthermore, 
inhibition of mTORC2 by LY would compromise the phosphorylation of Ser473 
and the subsequent phosphorylation at Thr308 of Akt necessary for its full activation 
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[14].  In addition, its inhibition of mTORC1 would have a more direct impact on 
4E-BP1 as compared to Akt inhibitor IV which acts upstream. However, the 
greater effect of LY did not result in a more pronounced inhibition of RC enzyme 
activities.  This may suggest that RC activities are more directly affected by Akt 
kinase since the Akt inhibitor IV has been reported to compromise the Akt 
autokinase activity more significantly than wortmanin, another PI3K inhibitor 
[106].  No attempt is made to correlate the degree of inhibition of enzyme activities 
with protein expressions of the RCs as Western blot analysis depends on only one 
of several subunits present in the RC, whereas enzyme activity measures the 
functionality of the composite RC. A differential mechanism of action of the two 
inhibitors was also inferred from the distinct band shifts in 4E-BP1 and its 
phosphorylated form by LY which was not apparent with Akt inhibitor IV. 
 Although our data of LY and Akt inhibitor IV described above provide a 
plausible relationship between Akt, 4E-BP1 and RC expressions, siRNA targeting 
4E-BP1 is deemed necessary to establish unequivocally a direct association 
between 4E-BP1 and RC expressions. In eukaryotes, protein synthesis is mainly 
regulated by 4E-BP1, a repressor of 5’cap-dependent translation [115].  4E-BP1, a 
downstream target of mTORC1, binds eIF4E to inhibit protein translation.  On 
phosphorylation, it detaches from eIF4E to initiate protein translation [18].  With 
gene silencing of 4E-BP1, expressions of RC I to V were up-regulated in MEFWT.  
Likewise, PTEN gene silencing showed a similar effect.  The first suggestive 
evidence of an involvement of translational regulation was the observation of a 
drastic reduction of this translational repressor in MEFPTEN-/-. To examine if up-
regulation is peculiar to the RCs, we measured the expressions of assorted proteins 
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(namely cytosolic proteins: ME 1, LDH-V and mitochondrial proteins: HKII, 
UCP2, ACO2, Bcl-2 and VDAC) besides RCI to V, following silencing of 4E-BP1 
(Fig.3.2.7). Of these, only the RCs were up-regulated which appeared to suggest 
some degree of specificity of 4E-BP1 regulation on the electron-transport proteins. 
In a parallel pathway, mTOR phosphorylates and activates the ribosomal protein 
S6 kinase (S6K) to promote protein translation [16]. In consideration of the fact 
that S6K inhibits PI3K signaling [16] and it is dispensable for tumorigenesis [23], 
its role on the protein translation of RCs was yet examined in this study. More 
work should be carried out in the future to validate the effect of S6K on the protein 
translation of RCs. 
 Generally, the selection of mRNAs for translation is exerted at the initiation 
stage with binding of elF4F complex to 5’-end of each mRNA and interaction 
between 3’UTR binding proteins and 4E-BPs [20].  The binding of the mRNA 
binding proteins of the Pumilio (PUF) family to the 3’ UTR can control mRNA 
stability and translational repression [21] to provide some measure of selectivity.  
Of all the Pufs indentified in yeast, Puf3p has been shown to bind nearly 
exclusively to nuclear encoded mitochondrial mRNAs [116, 117].  Mitochondrial 
mRNAs, which essentially code for the assembly factors of respiratory chain 
complexes and the mitochondrial translation machinery are highly dependent on 
the presence of Puf3 [118].  Taken together, we concluded that it is not impossible 
for 4E-BP1 to regulate expressions of mitochondrial RCs in a selective manner.  
However, post-translational modification of enzyme activities cannot be ruled out 
as several subunits of RCI were predicted from proteomic studies to be potentially 
capable of phosphorylation, e.g. tyrosine phosphorylation of RCI and RCV [119, 
54 
 
120].  Transcriptional control was deemed unlikely as there was no significant 
difference in the mRNAs of several subunits of the RCs between MEFPTEN-/- and 
the WT. Furthermore, the protein expressions of the transcription factor PGC-1α 
and its associated downstream targets, NRF-1 and mtTFA were similar between 
MEFPTEN-/- and the WT.  Our conclusion concurred with the report that the 
regulation of mitochondrial function by mTOR is independent of transcription 
[121].   
 
 In conclusion, the hyperactivated Akt confers on MEFPTEN-/- a bioenergetic 
advantage by up-regulating their oxidative mitochondrial functions.  We propose 
the enhanced mitochondrial  capacity in MEFPTEN-/- is used to support their higher 
rate of proliferation upon substrate availability.   Increased OXPHOS has been 
shown in H-Ras transformed fibroblast [122] and this bestows a proliferative 
advantage to K-Ras-mediated tumorigenecity [123] and provides energy to 
transformed human mesenchymal stem cells [124]. Our hypothesis that 
mitochondrial respiratory capacity is regulated by the Akt/mTOR/4E-BP1 cascade 
is summarized in Fig. 3.3.1.  Supporting evidence was provided using known small 
molecules as inhibitors of this signaling pathway and siRNA to knockdown PTEN 
or 4E-BP1 to demonstrate the link between PTEN/Akt/mTOR/4E-BP1 signaling 
and protein expressions of the electron transport respiratory complexes.  Our study 
has highlighted the role of 4E-BP1 in mitochondrial function in the early-






Fig 3.3.1   A proposed model of crosstalk between Akt/mTOR/4E-BP1 
signaling pathway and mitochondria. PTEN knockout in mouse embryonic 
fibroblasts (MEFPTEN-/-) results in an accumulation of PIP3 produced by PI3K at the 
plasma membrane. The recruitment of Akt and phosphoinositide-dependent protein 
kinase 1 (PDK1) by PIP3 is mediated via their pleckstrin homology (PH) domains.  
The phosphorylation at Ser473 by mTORC2 and that at Thr308 by PDK1 leads to a 
fully activated Akt [14] which then phosphorylates mTORC1. 4E-BP1, the 
downstream target of mTORC1, on phosphorylation becomes inactive as a 
repressor of protein translation as it is not able to bind to eIF4E [18]. This leads to 
the initiation of protein translation of RC components as shown in this study, 
contributing to enhanced OXPHOS in MEFPTEN-/-.  Likewise, knockdown of PTEN 
in MEFWT or of 4E-BP1 in MEFWT and MEFPTEN-/- by RNA silencing also increased 
RC expressions.  Conversely, attenuation of the hyper-activated Akt in MEFPTEN-/- 
by LY294002 or Akt inhibitor IV leads to lower RC activities and expressions. 
Together, the data presented supports our hypothesis of a link between 






3.4 EXPERIMENTAL PROCEDURES 
Cell culture - The MEFWT and MEFPTEN-/- cell lines [12] were kindly provided by 
Dr. Tak W. Mak of University of Toronto.  They were cultured in DMEM (Sigma, 
D1152) with 100U/ml penicillin, 100µg/ml streptomycin, 2mM glutamine and 10% 
fetal bovine serum in 5% CO2 at 37°C. 
Respiratory flux - The measurement of respiratory flux in intact MEF cells in a 
high-resolution respiratory system (Oroboros, Oxygraph-2k) was carried out 
according to the protocol described [125]. Cellular routine (R) state was established 
with the presence of cells in 2ml of culture medium in the chamber at 37°C with 
constant stirring for 15-30 min.  In the absence of exogenous substrates, the R 
(routine) respiration is dependent on endogenous substrates and substrates present 
in the culture medium.  Following the stabilization of R, oxygen consumption is 
measured in the presence of 2µg/ml oligomycin to obtain the Leak (L) state. In this 
non-physiological state, L respiration reflects intrinsic uncoupling of the 
mitochondria. Subsequently, a maximal electron transport system capacity (E) of 
the mitochondria is achieved by titrating sequentially with repeated doses of 1µl 
containing 1µM FCCP until a maximal response is achieved.  The net Routine/E is 
then calculated by applying the formula: Net routine/E = (R-L)/E.  This parameter 
therefore represents the net oxygen consumption coupled to ATP biosynthesis, 
taking into account the leak component. 
Isolation of mitochondria - The procedure described in [126] was used with slight 
modifications.  Cells were trypsinized, centrifuged at 1000g for 5 min and the 
pellet was re-suspended in 1ml of medium containing 250mM sucrose, 20mM 
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Hepes, 10mM KCl, 1.5mM MgCl2, 1mM EDTA and 1mM EGTA, pH 7.4.  This 
was followed by homogenization with 40 up-and-down strokes using a hand-held 
glass pestle.  The mixture was then centrifuged at 800g for 10 min and the 
supernatant so obtained was subjected to another step of centrifugation at 14,000g 
for 15min.  The final pellet was re-suspended in the same medium and was used 
immediately for ATP biosynthesis and measurement of MMP or kept at -80°C as 
freeze-thawed mitochondrial extracts for other enzyme assays. 
ATP biosynthesis - ATP production in 5 min was measured from the oxidation of 
the following substrates ± inhibitor: 10mM succinate + 5µM rotenone, 5mM each 
malate/glutamate, or 5mM ascorbate and 1mM tetramethylphenylenediamine 
(TMPD) + 2µg/ml antimycin A.  125µM ADP and 30µg mitochondrial protein 
were used in the reaction which was stopped by placing the tubes in a heating 
block at 100ºC for 3 min, followed by centrifugation at 14,000g for 15 min. ATP 
formed was measured by the luciferin/luciferase reaction in 5 min and the 
luminescence produced was read in a luminometer (Victor 3, Perkin-Elmer) as 
described previously [127, 128].   
Measurement of mitochondrial membrane potential (MMP) - The membrane 
potential was measured in isolated mitochondria using JC-1, a specific 
mitochondrial probe, by a change in the ratio of red fluorescence of the J-
aggregates to that of the green fluorescence of its monomers at Ex/Em wavelengths 
of 485/595nm and 485/535 nm, respectively.  Routinely, 0.2µM JC-1, 125µM ADP 
and 0.5mg of mitochondrial protein were used with the following added 




Activities of tricarboxylic acid  cycle  (TCA) enzymes – Assay conditions for 
measuring citrate synthase (CS) malate dehydrogenase (MDH) and glutamate 
dehydrogenase (GDH) in the freezed-thawed mitochondrial extracts have been 
described previously [46].    
NADH dehydrogenase or RCI – The enzyme activity of RCI was measured by a 
decrease in fluorescence of NADH in 5 min at excitation wavelength 352nm and 
emission wavelength 464nm using decylubiquinone as an electron acceptor [129].  
A mitochondrial extract containing 20µg protein was added to a respiratory buffer 
of pH 7.2 containing 25mM KH2PO4, 2mM NaN3, 5mM MgCl2, 64µM 
decylubiquinone, 2mg/ml albumin and 25µM NADH.  
Succinate dehydrogense or RCII  -  The assay was based on a decrease in 
absorbance of 2,6-dichlorophenolindolephenol (DCPIP) at 600nm monitored for 5 
min, with decylubiquinone as an acceptor [130]. A mitochondrial extract 
containing 30µg protein was employed in the presence of 1µM rotenone, 2µg/ml 
antimycin A and 2mM NaN3 to inhibit RCI, III and IV, respectively.  A pre-
incubation with succinate was carried out at 37°C for 5 min with the mitochondrial 
extract to overcome the known inhibitory effect of oxaloacetate on RCII. 
Ubiquinol dehydrogenase or RCIII – This activity was measured by a coupled 
assay using reduced decylubiquinone and cytochrome c (cyt c) as described [131].  
The assay was started by adding 50µM cyt c to a buffer containing 250mM sucrose, 
1mM EDTA and 50mM Tris-HCl, pH 7.4 and 30µg mitochondrial protein.  The 
absorbance of reduced cyt c was followed for 5min at 550nm. 
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Cytochrome c oxidase or RCIV - The assay measured the rate of decrease of 
reduced cyt c as reported previously [132].  Cyt c was first reduced by adding 4mg 
ascorbate to 10mg/ml cyt c.  The reaction was started by adding 80µg 
mitochondrial protein to a solution containing 4mM KH2PO4 (pH 7.2) and 65-
70μM reduced cyt c.  The decrease in absorbance of reduced cyt c was followed at 
550nm for 20sec. 
FoF1-ATPase or RCV – This was measured by coupling the ADP formed to 
pyruvate kinase using phosphoenolpyruvate as the substrate. Pyruvate formed was 
reduced to lactate by lactate dehydrogenase (LDH) as described previously [132, 
133].  The decrease in NADH was monitored for 10 min at 340 nm in an 
absorbance microplate reader. 
Determination of mitochondrial protein – The protein concentrations of the 
mitochondrial fraction and the whole cell lysate prepared from MEFWT and 
MEFPTEN-/- were determined by the bicinchoninic acid assay [134]. The purity of 
the mitochondrial fraction was examined by Western blot analysis using the 
mitochondrial and cytosolic markers, voltage dependent anion channel (VDAC) 
and Cu-Zn superoxide dismutase (SOD-1), respectively.  
Western blot analysis - Aliquots of the mitochondrial or cytosolic fractions or total 
cell lysates containing 50µg protein were subjected to electrophoresis on sodium 
dodecyl sulfate-polyacrylamide gel and electro-blotted onto a nitrocellulose 
membrane.  After blocking with 10% non-fat milk in TBS with 0.1% Tween-20, 
the membranes were probed with  the respective primary antibodies of PTEN, Akt,  
p-Ser473Akt, p-Thr308Akt, 4E-BP1, p-Thr37/46 4E-BP1, B-cell lymphoma 2 (Bcl-2) 
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(Cell Signaling Technology, Beverly, MA, USA), VDAC (Calbiochem, San Diego, 
CA, USA) malic enzyme 1 (ME 1), hexokinase II (HKII), SOD-1 (Santa Cruz 
Biotechnology, CA, USA), lactate dehydrogenase isoenzyme V (LDH-V) (Abcam, 
Cambridge, UK),  uncoupling protein 2 (UCP2) (Alpha Diagnostic, Texas, USA), 
and aconitase 2 (ACO2) (Abgent, San Diego, CA  USA). Western blot analyses of 
the respiratory complexes were carried out using a cocktail containing antibodies 
against the following subunits of the five RCs: complex I subunit NDU FB8, 
complex II subunit 30kDa (SdhB), complex III subunit Core 2 (RC III core 2), 
complex IV subunit I (CO1) and ATP synthase α-subunit (ATP5 F1α1) 
(MitoSciences, Oregon, USA). All primary antibodies were used at a dilution of 
1:1000 except for α-tubulin and pan-actin, the loading controls, which were diluted 
1:20000.  Anti-goat pan-actin was used as the loading control for the Western blot 
analyses of the respiratory complexes because the α-subunit of ATP synthase and 
α-tubulin of same species (mouse) have similar molecular weight and therefore 
cannot be resolved.  
Inhibition by LY294002 and Akt inhibitor IV - Briefly, MEFPTEN-/- grown to 70% 
confluence were pre-incubated with either 25µM LY for 4h or 1µM Akt inhibitor 
IV for 8h prior to enzymatic assays and Western blot analyses. 
RNA extraction and reverse transcription - Total RNA from MEFWT and MEFPTEN-
/- was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to 
the manufacturer’s instructions. 500ng RNA was reverse transcribed using 1µl of 
ImPromII reverse transcriptase and 0.5µg random hexamer for 60 min at 42°C and 
terminated at 70°C for 5min according to the instruction from the manufacturer 
(Promega, Madison, WI, USA).  
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Primers and real-time PCR –  The mRNAs of the same five RC subunits detected 
in Western blot analyses were quantified by real-time PCR by using their 
respective forward and reverse primers as shown in Table 3.4.  Mouse alpha 1A 
tubulin (forward primer: 5’-TCGATGAAGTTCGCACCG-3’, 5’-reverse primer: 
TATTGGCAGCATCCTCCT-3’) was used as an internal control for normalization.  
Real time PCR using SYBR Green I was performed on the iCycler iQ (Biorad, 
Hercules, CA, USA) in a total volume of 25 µl containing 1 x Xtensa-Mix-SG 
(BioWORKS, Singapore), 1µl of cDNA sample, 2.5 mM MgCl2, 0.2µM of each 
primer, and 0.5U KlearTaq DNA polymerase (KBiosciences, Hertfordshire, UK).  
Real-time PCR was carried out after an initial denaturation of 10min at 95°C 
followed by 40 cycles of 20s denaturation at 95°C, 20s annealing at 60°C and 20s 
extension at 72°C.  Detection of fluorescence was carried out at the annealing 
phase. The threshold cycles (Ct) were calculated automatically using the iQ5 
software (Bio-Rad). 
SiRNA targeting PTEN and 4E-BP1 - Gene silencing of PTEN on MEFWT and of 
4E-BP1 on both MEFWT and MEFPTEN-/- were carried out using small interference 
RNAs.  Cells at 60-70% confluence were transfected for 16h with either (a) 20nM 
PTEN (sense: CGAUCUUGACAAAGCAAACtt, antisense: 
GUUUGCUUUGUCAAGAUCGtt purchased from Ambion, NY) or (b) with 4E-
BP1-targeting RNA which consists of a pool of 3 target-specific 4E-BP1 siRNAs 
(product no. sc-29595 from Santa Cruz Biotechnology, CA, USA) or (c) with non-
targeting RNAs (r(UUCUCCGAACGUGUCACGU)d(TT) and 
r(ACGUGACACGUUCGGAGAA)d(TT) from Qiagen, Hilden, Germany).  
Following 18h of recovery in normal culture medium, the efficiency of knockdown 
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of PTEN and 4E-BP1 and their effects on respiratory flux and RC expressions were 
measured.  
Statistical Analysis - Data were presented as means ± SD, and were analyzed by the 
Student’s t-test where a p value of < 0.05 was considered significant. 
 







































Table 3.4 Primers used in Real-time PCR. mRNAs of subunits (encoded by 
mitochondrial and nuclear DNAs) of respiratory complexes were measured using the 








CHAPTER 4  AKT UPREGULATES 
MITOCHONDRIAL CHOLESTEROL, LEADING TO 
LOWER PROTON LEAK AND HIGHER ROS 
PRODUCTION 
4.1 INTRODUCTION 
 Cholesterol is a critical component of biological membranes. It plays an 
important role in controlling the physical properties of membrane and signal 
transduction [135]. While the pathogenesis of cholesterol has been recognized in 
cardiac and brain vascular diseases, recent studies have shown the accumulation of 
cholesterol in prostate and renal carcinoma [136, 137]. Elevated cholesterol had 
been found in lipid raft to promote tumor growth via the activation Akt [138, 139], 
a serine/threonine kinase that is essential for survival and proliferation in cancer 
[140]. Akt can also induce cholesterol biosynthesis [141], which may explain the  
accumulation of cholesterol in cancers. 
 Although mitochondria are involved in steroidogenesis, they are relatively 
cholesterol-poor organelles, containing only 0.5-3% of the amount found in the 
plasma membrane [142]. This implies that the homeostasis of mitochondrial 
cholesterol is tightly regulated, possibly by the steroidogenic acute regulatory 
protein (StAR) uptake transporter and/or the ATP binding cassette (ABC) 
transporter A1 [143, 144]. The unphysiological accumulation of cholesterol in 
mitochondria had been reported in hepatoma [111, 145, 146] which would 
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conceivably render these organelle more resistant to conformational change [146] 
and to chemotherapy as shown in hepatocellular carcinoma [143].  
 While most of the studies had focused on mitochondrial cholesterol and cell 
survival in cancers [143, 144, 147], little is known about the effect of 
mitochondrial cholesterol on respiration. Given that the generation of ATP relies 
on the proton motive force (∆ p), which in turn, depends on the permeability of 
inner mitochondrial membrane to proton, dysregulated cholesterol homeostasis in 
mitochondrial membrane could have an impact on the normal mitochondrial 
physiology. Lower proton leak has been found to be associated with higher 
mitochondrial cholesterol content [111]. In general, proton leak contributes to a 
significant portion of resting state respiration and it primarily functions to generate 
heat and to reduce the production of reactive oxygen species (ROS) [148]. As the 
mitochondrial membrane potential (MMP/∆ ψm) is a driving force of ROS 
generation [149-151], it is not surprising that both MMP and ROS are high in 
cancer [88, 152] which provided the mechanism of the reduction of ROS mediated 
by proton leak to suppress skin carcinogenesis [153]. On the other hand, proton 
leak prevented by genipin, an inhibitor of uncoupling protein 2 (UCP 2), sensitizes 
drug-resistant cancer cell to anti-cancer drugs by up-regulating ROS production 
[154].  
 In view of the implication of mitochondrial cholesterol, Akt hyperactivation 
and higher ROS production in carcinogenesis, the present study investigated the 
potential role of hyperactivated Akt on cholesterol accumulation in mitochondria 
and its effect on proton leak and ROS production. The proton leak was determined 
by measuring the oxygen consumption in the absence of ATP synthesis (leak 
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respiration) [125, 149, 155, 156]. Using the human breast epithelial MCF10 series 
of cell lines, MCF10A1 (benign) vs. MCF10CA1a (malignant), we found that 
higher mitochondrial cholesterol in MCF10CA1a was correlated to lower proton 
leak. Furthermore, the reduced proton leak was accompanied by higher MMP and 
ROS generation. Our study with lovastatin, StAR protein knockdown and assays of 
cholesterol enrichment/depletion in vitro demonstrated the potential therapeutic 













4.2.1 Hyperactivated Akt in MCF10CA1a is associated with lower proton leak, 
higher mitochondrial membrane potential (MMP) and mitochondrial (mt-) 
ROS production 
 The malignant MCF10CA1a cells showed higher protein expressions of 
phosphorylated Akt (p-Ser473 Akt and p-Thr308 Akt) (Fig. 4.2.1A) and higher 
content of mitochondrial cholesterol as compared to MCF10A (Fig. 4.2.1B). 
Preliminary partial purification of mitochondria with Percoll gradient 
centrifugation was attempted to exclude possible contamination of mitochondria-
ER-associated membrane (MAM) [157]. This step had little to no effect on 
mitochondrial cholesterol measurement (data no shown) and was excluded. In 
addition, a lower proton leak was noted with a higher MMP and higher production 
of mitochondrial ROS (Fig. 4.2.1B). Overall, Akt hyperactivation in MCF10CA1a 
cells showed higher mitochondrial cholesterol, MMP and mitochondrial ROS 





Fig. 4.2.1 Hyperactivated Akt in MCF10CA1a is associated with higher 
mitochondrial (mt) cholesterol, lower proton leak, higher mitochondrial 
membrane potential (MMP) and higher production of mitochondrial ROS. A. 
MCF10CA1a with Akt hyperactivation in showed higher protein expressions of p-
Ser473Akt and p-Thr308Akt. B. The higher  mt cholesterol content is associated with 
lower proton leak, higher mitochondrial membrane potential (MMP) and 
production of mitochondrial reactive oxygen species (ROS) in MCF10CA1a as 
compared to MCF10A1. Mitochondrial cholesterol was measured in isolated 
mitochondria, whereas proton leak, MMP and production of mitochondrial ROS 
were measured in intact cells. * p < 0.05, ** p < 0.01, # p < 0.005 for n = 3. 
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4.2.2 Mitochondrial cholesterol and associated changes in proton leak, MMP 
and production of mitochondrial ROS  
(a) Gene silencing of PTEN in MCF10A 
 Akt hyperactivation was induced in the benign MCF10A1 by silencing 
PTEN using small interference RNA (si-PTEN). Gene silencing on PTEN in 
MCF10A1 resulted in the higher protein expressions of p-Ser473Akt and p-
Thr308Akt (Fig. 4.2.2A). PTEN knockdown was accompanied by higher 
mitochondrial cholesterol, lower proton leak, higher MMP and higher production 
of mitochondrial ROS (Fig.4.2.2B). These profiles were similar to those in 





Fig. 4.2.2. The effect of gene silencing of PTEN on mitochondrial cholesterol, 
proton leak, MMP and production of mitochondrial ROS. A. Akt 
hyperactication was induced in MCF10A1 by small interference RNA targeting 
PTEN (si-PTEN) which resulted in increased protein expressions of p-Ser473Akt 
and p-Thr308Akt. B. Gene silencing of PTEN in MCF10A1 increased mitochondrial 
cholesterol, MMP and mitochondrial ROS production but reduced proton leak. ** 








(b) Inhibition of Akt by Akt inhibitor IV in MCF10CA1a 
 Inhibition of hyperactivated Akt in MCF10CA1a by Akt inhibitor IV had 
hampered the Akt hyperactivation as shown by the lower protein expressions of p-
Ser473Akt and p-Thr308Akt (Fig. 4.2.3A). This was accompanied by a lower 
mitochondrial cholesterol content with higher proton leak, lower MMP and lower 
mitochondrial ROS production (Fig. 4.2.3B). To summarize, Akt signaling was 
implicated in these four parameters with higher mitochondrial cholesterol was 
positively correlated with MMP and mitochondrial ROS production and negatively 




Fig. 4.2.3. Akt inhibition by Akt inhibitor IV. A. Akt inhibitor IV inhibited Akt 
hyperactivation in MCF10CA1a as evident by the decrease of protein expressions 
on p-Ser473 and p-Thr308 Akt. B. This resulted in lower mitochondrial cholesterol, 
MMP and mitochondrial ROS production and enhanced proton leak. *p < 0.05, # p 








4.2.3 Does mitochondrial cholesterol contribute to proton leak, MMP and 
mitochondrial ROS production? 
 Five different procedures in vitro were employed to modulate the content of 
mitochondrial cholesterol. 
 (1) Enrichment of cholesterol on MCF10A1/CA1a mitochondria 
i. Cholesterol-BSA-cholesterol (C-BSA-C) complex 
Incorporation of cholesterol was carried out on mitochondria isolated from 
MCF10A1 whose basal cholesterol content was lower as compared to 
MCF10CA1a (Fig. 4.2.1B) using C-BSA-C complex as described in "Materials and 
Methods". An increase of ~20% mitochondrial cholesterol was observed as 
compared to control (Fig. 4.2.4). Such a magnitude of increase had been reported 
previously [158]. The increase in cholesterol content had elicited a decrease in 




Fig. 4.2.4 Enrichment of mitochondrial cholesterol by cholesterol-BSA-
cholesterol (C-BSA-C) complex. Cholesterol incorporation using a standard 
procedure with C-BSA-C complex increased mitochondrial cholesterol content by 
only ~20%. Cholesterol enrichment was accompanied by lower proton leak, higher 
MMP and ROS production. All the parameters were examined using isolated 








ii. Gene silencing on ATP binding cassette transporter A1 (ABCA1) in 
MCF10CA1a 
 Similarly, mitochondrial cholesterol was enhanced by silencing the ABCA1 
using small interference RNA. The knockdown efficiency of ABCA1 was shown in 
Fig. 4.2.5A.  Higher mitochondrial cholesterol was accompanied by lower proton 






Fig. 4.2.5 Gene silencing of ATP binding cassette transport A1 (ABCA1). A. 
The small interference RNA targeting ABCA1 had reduced the protein expression 
of ABCA1. B. Higher mitochondrial (mt) cholesterol, mitochondrial membrane 
potential (MMP), the production of ROS and lower proton leak were observed in 









(2) Depletion of mitochondrial cholesterol on MCF10CA1a 
i.  Methyl-β-cyclodextrin (MβCD) 
 Conversely, MCF10CA1a was chosen for cholesterol depletion. The degree 
of depletion of mitochondrial cholesterol by MβCD was ~30%. This was 
associated with higher proton leak and lower MMP and lower production of ROS 
(Fig.4.2.6). These observations were the reverse of cholesterol enrichment shown 
previously in Fig. 4.2.4.  
Fig. 4.2.6. Depletion of mitochondrial cholesterol by methyl-β-cyclodextrin 
(MβCD). Cholesterol of mitochondria isolated from MCF10CA1a was depleted 
using methly-β-cyclodextrin (MβCD). Mitochondria with lesser cholesterol had 
higher proton leak, lower MMP  and lower ROS production. All parameters were 
assessed using isolated mitochondria. **p < 0.01, # p < 0.005 for n = 3. 
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ii. Gene silencing on the steroidogenic acute regulatory protein (StAR)  
 Next, mitochondrial cholesterol was depleted by silencing the StAR, a 
mitochondrial cholesterol importer [159]. This had reduced both the protein 
expression of StAR and mitochondrial cholesterol content in MCF10CA1a (Fig. 
4.2.7A and B). The reduction in the mitochondrial cholesterol was accompanied by 
an increase in proton leak, which in turn, reduced MMP and the production of 




Fig. 4.2.7. Gene silencing on the steroidogenic acute regulatory protein (StAR). 
The StAR was silenced in MCF10CA1a using small interference RNAs as 
described in "Materials and Methods". This had reduced the protein expression of 
StAR (A) and led to lower mitochondrial cholesterol content (B). Higher proton 
leak with reduced MMP and the production of mitochondrial ROS were observed 
in MCF10CA1a with gene silencing of the StAR (B). Proton leak, MMP and 
mitochondrial ROS production were assessed using intact cells. ** p < 0.01,  # p < 









 Mitochondrial cholesterol was depleted using lovastatin as described in the 
"Materials and Methods". Lovastatin is an inhibitor of HMG-CoA reductase; the 
latter catalyses the first committing step in the biosynthesis pathway of cholesterol. 
Lovastatin reduced the mitochondrial cholesterol content in MCF10Ca1a 
(Fig.4.2.8A). Lower cholesterol content was associated with higher proton leak, 
lower MMP and lower production of mitochondrial ROS (Fig.4.2.8A). To confirm 
that the effect of lovastatin on MMP and ROS production were mediated by 
mitochondrial cholesterol, cholesterol incorporation was carried out on the 
mitochondria isolated from MCF10CA1a which was pre-treated with lovastatin. 
This had recovered the loss of MMP and mitochondrial ROS production in 











Fig. 4.2.8. Depletion and recovery of mitochondrial cholesterol in 
MCF10CA1a by lovastatin and C-BSA-C. (A) Lovastatin reduced mitochondrial 
cholesterol content and that was associated with higher proton leak, lower MMP 
and mitochondrial ROS production. Proton leak, MMP and the production of 
mitochondrial ROS were measured using intact cells. Mitochondrial cholesterol 
was recovered by incorporating C-BSA-C complex onto mitochondria isolated 
from MCF10CA1a treated with lovastatin. (B) This had recovered almost all the 
mitochondrial cholesterol and led to higher MMP and higher production of 
mitochondrial ROS. Mitochondria incubated with BSA-only was used as a control. 




4.2.4 Proton leak contributes to lower MMP and mitochondrial ROS 
production 
 We next studied if proton leak contributes to lower MMP and lower 
production of mitochondrial ROS. Using genipin to prevent proton leak from 
uncoupling protein 2 (UCP 2), we inhibited proton leak in MCF10A1 (Fig. 4.2.9). 
Lower proton leak in MCF10A1 induced higher MMP and production of 
mitochondrial ROS (Fig. 4.2.9). Fig. 4.2.9A showed the presence of UCP 2 in both 












Fig. 4.2.9. The effects of genipin on proton leak, MMP and mitochondrial ROS 
production. Genipin was used to inhibit proton leak from uncoupling protein 2 
(UCP 2) in MCF10A1, which had higher basal proton leak as compared to its 
malignant counterpart (Fig. 4.2.1B). Lower proton leak induced by genipin had 
enhanced MMP and production of mitochondrial ROS. Proton leak, MMP and 








 Unphysiological accumulation of cholesterol in hepatoma mitochondria had 
been reported [143, 145, 146]. Apart from providing resistance to conformational 
change of the mitochondrial membrane [146, 160] and prevent apoptosis [143, 144, 
158], the effect of mitochondrial cholesterol on respiratory functions is unknown. 
Using human breast cell line MCF10Ca1a with hyperactivated Akt as the study 
model, we showed that mitochondrial cholesterol accumulation was regulated by 
Akt signaling. The higher mitochondrial cholesterol content was associated with 
lower proton leak, higher MMP and mitochondrial ROS production. Notably, 
similar results on proton leak were obtained using mouse embryonic fibroblast 
PTEN knockout with constitutively hyperactivation of Akt  ([28] and data not 
shown). Since Akt is implicated in cholesterol biosynthesis [141] and the 
cholesterol accumulation on lipid raft could lead to Akt activation [138, 139], the 
positive feedback mechanism of Akt and cholesterol homeostasis could explain the 
Akt hyperactivation [161] and cholesterol accumulation in prostate and breast 
cancers [136, 162].  
 While it is difficult to measure the proton leak directly, it can be estimated 
by measuring the oxygen consumption in the absence of ATP synthesis  [149, 156]. 
This approach appeared to be the only de facto measure of proton leak [150]. 
Generally, proton leak is well-recognized as a mechanism to dissipate some of the 
free energy stored in proton motive force (∆ p) for thermogenesis [151]. However, 
the observation of the proton leak in poikilotherms alluded that it may have 
additional physiological functions besides heat generation [156]. Indeed, given that 
the generation of ROS from the reverse electron transport of ubiquinone cycle [163] 
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is dependent on MMP and ∆ p [164, 165]; proton leak was proposed to minimize 
the ROS production by tempering MMP and ∆ p [166]. This was supported by the 
study on the reduction of proton leak through the inhibition of uncoupling protein 2 
(UCP 2) which had sensitized the drug resistant cancer cells to cytotoxic agent by 
up-regulating ROS production [154]. Thus, proton leak appears to have the tumor 
suppressive property as ROS are involved in all the stages in tumorigenesis [77, 
88]. Although mitoSOXTM is mainly used to detect mitochondrial superoxide 
production (information by the supplier, Life TechnologiesTM), similar results were 
obtained with DCF-DA in intact cells and isolated mitochondria (data not shown) 
suggesting a general increase in cellular and mitochondrial ROS content in Akt 
hyperactivated cells.  
 Despite statins were originally developed to resolve the pathological 
problems resulted from cholesterol accumulation in cardiovascular diseases, this 
group of drugs appear to have vast unexploited potential in other human diseases, 
particularly in cancer prevention [167]. Nevertheless, the harmful effects associated 
with statins should not be overlooked. In consideration of the fact that the statins 
inhibit HMG-CoA reductase, an upstream enzyme of mevalonate pathway, the 
biosynthesis of downstream molecules will be affected [168]. For instance, the 
statins-associated myopathy is caused by the reduction in coenzyme Q10 [169]. 
Such side effects hinder statins as a monotherapy for cancer treatment [170]. 
Alternatively, our data suggested the feasibility of targeting mitochondrial 
cholesterol in cancers. We showed for the first time that the implication of the 
steroidogenic acute regulatory protein (StAR) on mitochondrial ROS production. 
The StAR is located on the outer mitochondrial membrane (OMM) and functioned 
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as a transporter to facilitate the import of cholesterol from OMM to inner 
mitochondria membrane (IMM) [159]. The gene silencing on StAR therefore 
reduced the mitochondrial cholesterol content, leading to the observation on higher 
proton leak, lower MMP and ROS production. Although located at plasma 
membrane, both the caveolin1 (CAV1) and the ATP binding cassette transport A1 
(ABCA1) are implicated in regulating the homeostasis of the mitochondrial 
cholesterol  [144, 158]. Particularly, CAV1-/- in mice promoted the accumulation of 
cholesterol at mitochondrial membrane, leading to higher MMP and production of 
ROS [158]. Similarly, deficiency of ABCA1 enhanced mitochondrial cholesterol 
[144] and linked to more aggressive phenotype in human breast cancer patients 
[171].   
 While the mechanistic action of mitochondrial cholesterol on proton leak 
remains unknown, the effect of mitochondrial cholesterol on membrane fluidity is 
well-documented [143, 158, 160, 172]. The proton leak across mitochondrial inner 
membrane is dependent on the lipid composition, the higher the unsaturated index, 
the higher proton leak [149, 151, 156]. Indeed, cholesterol reduces the spatial 
mobility of the components in electron transport chain therefore enhances 
production of mitochondrial superoxide [173]. Given that the accumulation of 
mitochondrial cholesterol impairs the import of glutathione into mitochondria, 
which could also account for higher ROS production observed in cholesterol-
accumulated mitochondria [158], our data from isolated mitochondria suggested 
that the MMP could be the major factor in driving the production of ROS. 
 In conclusion, the present study demonstrated the oncogenic action of Akt 
signaling on the production of ROS was mediated through mitochondrial 
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cholesterol content. Since higher oxygen consumption is required to maintain 
proton motive force in the presence of proton leak [149], the lower proton leak 
caused by higher mitochondrial cholesterol content may render tumor cells to 
survive in the hypoxic environment. While the inhibition of the protein prenylation 
has been the leading hypothesis of the potential anti-cancer effects of statins [168], 
our data showed for the first time that the statins may exert their anti-cancer 
property via tempering the production of mitochondrial ROS. The mechanism 
whereby Akt regulates proton leak and ROS production is illustrated in Figure 4.3. 
Supporting evidence was provided by using combinatorial approaches, namely 
small RNA interferences (targeting PTEN, StAR and ABCA1), inhibitors (Akt 
inhibitor IV and genipin), pharmacological drug (lovastatin), and chemical 
compounds such as FCCP, MβCD and C-BSA-C complex. Our study highlighted 









Fig. 4.3 A proposed model of PTEN/Akt signaling on proton leak, 
mitochondrial membrane potential and ROS production. MCF10CA1a with 
PTEN/Akt aberration were used as the models to study the effect of PTEN/Akt 
signaling on proton leak. Given that PTEN serves the crucial phosphatase to inhibit 
the accumulation of PIP3 on the membrane for the activation of Akt [97], PTEN 
knock down using small interference RNA could lead to hyperactivation of Akt. 
Besides genetic approaches, activated Akt can be inhibited by small molecule, such 
as the Akt inhibitor IV which competes at the ATP binding site of Akt and leads to 
the inactivation of Akt [106]. Both the inhibition on PTEN and Akt had negative 
and positive impact on proton leak respectively. Particularly, the proton leak 
regulated by PTEN/Akt signaling appeared to be modulated through mitochondrial 
cholesterol. We used a combinatorial approaches (enrichment of mitochondrial 
cholesterol: C-BSA-C and si-ABCA1; depletion of mitochondrial cholesterol: 
MβCD, si-StAR and lovastatin) to modulate the mitochondrial cholesterol for the 
study on the relationship between mitochondrial cholesterol and proton leak. Of 
note, the intactness of mitochondrial membrane affected by the mitochondrial 
cholesterol content had a direct impact on MMP and ROS production. Using 
genipin (an UCP 2 inhibitor) to prevent proton leak, we showed that proton leak is 
directly involved in MMP and ROS production. Together, the data support our 
hypothesis that the lower proton leak in PTEN/Akt is mediated by mitochondrial 
cholesterol content. Higher mitochondrial cholesterol prevents proton leak, leading 




4.4 EXPERIMENTAL PROCEDURES 
Materials and Methods 
Chemicals 
All chemicals were purchased from Sigma (St. Louis, MO, USA), unless specified 
otherwise. 
Cell culture and treatments 
MCF10 series cell lines namely MCF10A and MCF10CA1a [174] were purchased 
from ATCC and were cultured in DMEM/F-12 Ham (Gibco, Life TechnologiesTM) 
supplemented with  20ng/ml EGF, 100ng/ml cholera toxin, 10µg/ml insulin, 
0.5µg/ml hydrocortisone and 5% horse serum, in 5% CO2 at 37°C. Cholesterol 
biosynthesis in MCF10CA1a was inhibited by the 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitor, lovastatin, at concentration of 10μM 
for 16hr. Inhibition of uncouplin protein 2 (UCP 2) was carried out on 
MCF10A1with 10μM genipin for 1hr. 
Isolation for mitochondria 
Mitochondria from MCF10A and MCF10CA1a were isolated as reported 
previously [28]. The mitochondrial extract was used immediately for the 
measurements of mitochondrial cholesterol determination, MMP, ROS and proton 
leak as described below. 
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Determination of mitochondrial cholesterol 
Total mitochondrial cholesterol content was measured using the Amplex Red assay 
kit (InvitrogenTM) according to the protocol provided by the supplier. 
Mitochondrial cholesterol was first oxidized by cholesterol oxidase to yield H2O2 
which was then reacted with Amplex Red to produce the highly fluorescent 
resorufin and detected at excitation/emission wavelengths 571/585nm in a 
fluorescence plate reader (Varioskan, Thermo Scientific). 
Measurement of proton leak  
Proton leak measurement using intact cells  (0.5 million cells) or isolated 
mitochondria (0.25mg mitochondrial protein) was carried out in the high-resolution 
respiratory system (Oroboros, Oxygraph-2k) as described in [28, 125] and [155]. 
Mitochondrial membrane potential (MMP/ ∆ψm) measurement 
MMP was measured using the TMRM (tetramethylrhodamine methyl ester) dye. 
MCF10A series of cell lines (0.2 million cells) were incubated with 100nM of 
TMRM at 37°C for 5 min followed by washing with fluorescence-activated cell 
sorting (FACS) buffer containing 120mM KCl, 5mM KH2PO4, 3mM HEPES, 
1mM EDTA, 1mM MgCl2, pH 7.8 and re-suspension in the same buffer prior to 
the flow cytometric analysis (BD FACSCanto II; BD Biosciences). For MMP 
determination in isolated mitochondria, 20μg of mitochondrial protein was 
incubated with TMRM in the condition described above. The mitochondrial pellet 
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was collected by centrifugation at 14,000g for 15 min followed by washing and re-
suspension in FACS buffer prior to the flow cytometric analysis. 
ROS determination in whole cell and isolated mitochondria 
ROS was measured using the MitoSOX™ Red reagent according to manufacturer's 
recommendation. MCF10A series of cell lines (0.2 million cells) were incubated 
with 5µM MitoSOX™ Red reagent for 10 min at 37°C followed by washing in 
Hankʼs balanced salt solution, HBSS (supplemented with 1mg/ml glucose) and 
centrifuged at 500g and re-suspended in the buffer prior to flow cytometric analysis. 
For ROS determination using isolated mitochondria, the same concentration of 
MitoSOX™ Red reagent was incubated with 20μg of mitochondrial protein at 
37°C for 10 min. The mixture was then centrifuged at 14,000g for 15 min to collect 
the mitochondrial pellet followed by washing with HBSS prior to the flow 
cytometric analysis. 
Enrichment of mitochondrial cholesterol 
 
Cholesterol enrichment in isolated mitochondria from MCF10A1 was carried as 
described by Martinez et al [175]. Briefly, 0.25mg of mitochondrial protein was 
incubated with 1% cholesterol using bovine serum albumin as a carrier. Isolated 
mitochondria were incubated with cholesterol-bovine serum albumin-cholesterol 
complex (designated as C-BSA-C) on ice for 1 min and centrifuged at 14000g 
following 2 washings with sucrose-EDTA buffer [175] prior to the measurement of 




Depletion of mitochondrial cholesterol 
 
Cholesterol from isolated MCF10CA1a mitochondria (0.1mg) was depleted by 
incubation with 10mM methyl-β-cyclodextrin (MβCD) for 5min at room 
temperature [176]. This was followed by washing 2 times with sucrose-EDTA 
buffer and centrifuged at 14000g to collect the mitochondrial pellet for the 
measurement of mitochondrial cholesterol content, proton leak, MMP, and ROS 
production. 
 
Gene silencing on PTEN, steroidogenic acute regulatory protein (StAR) and ATP 
binding cassette transport A1 (ABCA1) 
Gene silencing of StAR and ABCA1 in MCF10CA1a or PTEN in MCF10A1 were 
carried out using small interference RNAs as described previously [28]. Briefly, 
cells at 60–70% confluence were transfected for 16 h with either (a) 20nM PTEN 
[28] or (b) StAR- or ABCA1- targeting RNA which consists of a pool of 3 target-
specific StAR or ABCA1 siRNAs (product no. sc-44121, sc-41136,  Santa Cruz 
Biotechnology, CA, USA) or (c) with non-targeting RNAs [28].  
Western-blot analysis 
Protein expressions of Akts, PTEN, StAR (FL-265, Santa Cruz Biotechnology, CA, 
USA), ABCA1 (ab18180, Abcam, Cambridge, UK), UCP 2 and α-tubulin were 
probed by following the procedures described previously [28]. All primary 
antibodies were used at a dilution of 1:1000 except for α-tubulin, the loading 




Data were presented as means ± SD, and were analyzed by the two-tailed Student’s 
















CHAPTER 5 ENHANCED ROS PRODUCTION 
CONFERS GLUTAMINE ADDICTION IN PTEN/AKT 
DYSREGULATED CELLS 
5.1 INTRODUCTION 
 Cancer cells have been associated with aberrant redox regulation [77, 177, 
178]. Mounting evidence suggests that the oxidative stress in cancers may have 
resulted from elevated metabolic activity, mitochondrial dysfunction, activation of 
oncogenes (e.g. c-Myc, Kras) or inactivation of tumor suppressors (e.g. p53) [77, 
123, 177-180]. While a high level of reactive oxygen species (ROS) is detrimental 
to the cells, a moderate increase of ROS is beneficial for the survival and 
development of cancer [88, 177]. Indeed, cancer cells have acquired several 
mechanisms to cope with the oxidative stress. For instance, the M2 isoform of 
pyruvate kinase (PKM2), which plays an important role in the generation of 
NADPH from the pentose phosphate pathway (PPP) is often found up-regulated in 
cancer cells [43]. In addition, several enzymes in the glutamine metabolism are up-
regulated to modulate redox regulation in cancer cells [69, 181]. Being the most 
abundant free amino acid in human plasma [182], it is therefore not surprising that 
glutamine plays a prominent role in diseases such as cancer.  
 PTEN/Akt is one of the most frequently dysregulated signalings pathway in 
cancers. We had  previously demonstrated that the PTEN/Akt up-regulates 
respiratory functions [28] which might lead to higher ROS production (manuscript 
in preparation/Chapter 4 and [7]). In this study, we proposed that PTEN/Akt up-
regulates antioxidant capacity via glutamine dependency to allow the cells to thrive 
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in an oxidative stress condition. We first demonstrated that cells with PTEN/Akt 
aberration had increased ROS production and was more sensitive toward glutamine 
deprivation. Notably, the glutamine addiction in PTEN/Akt aberrated cells was 
probably independent of c-Myc and KGA. Lastly, our data demonstrated that the 
up-regulated glutamine metabolism might be used for glutathione biosynthesis, as 
glutathione depletion by buthionine sulphoximine (BSO) had sensitized cells with 

















5.2.1 Glutamine addiction in PTEN aberrated cell lines 
We had recently demonstrated enhanced respiratory functions in highly 
proliferative MEFPTEN-/- [28]. Furthermore, glutamine has been shown to stimulate 
oxygen consumption and ROS production in Kras-mediated tumorigenicity [123]. 
To show that PTEN/Akt alters glutamine metabolism in the mouse embryonic 
fibroblasts (MEFs), we first deprived glutamine from the culture medium, which is 
usually supplemented with 2mM glutamine. As shown in Fig 5.2.1A, MEFPTEN-/- 
was more sensitive to glutamine deprivation, with lower cell viability as compared 
to wildtype in the absence and low glutamine (0.1mM). Furthermore, PTEN 
reconstruction in MEFPTEN-/- by over-expressing the complete (MEFPTEN-/- + 
PTEN)* but not the truncated/mutant PTEN (MEFPTEN-/- + mPTEN)* had rescued 
MEFPTEN-/- from glutamine deprivation (at 0 and 0.1mM of glutamine). Notably, 
0.5mM of glutamine appeared to be sufficient to stimulate higher cell proliferation 
in MEFPTEN-/- as compared to wildtype (Fig. 5.2.1A). Furthermore, a lower cell 
viability was observed in human malignant breast cell MCF10CA1a with 
PTEN/Akt dysregulation (manuscript in preparation/Chapter 4) as compared to its 
normal counterpart (MCF10A1) at 0 and 0.05mM of glutamine (Fig. 5.2.1B). 
Together, our data indicated that PTEN/Akt aberration rendered MEFPTEN-/- and 
MCF10Ca1a to higher glutamine dependency. 






Fig. 5.2.1 PTEN/Akt aberration confers glutatamine addiction A. The 
reduction in relative cell viability was more pronounced in MEFPTEN-/- as compared 
to wildtype cultured in media deprived of glutamine (0mM and 0.1mM). MEFPTEN-/ 
proliferated faster as compared to wildtype at 0.5mM of glutamine. Full length 
PTEN but not the mutant PTEN over-expression in MEFPTEN-/- (MEFPTEN-/- + 
PTEN vs. MEFPTEN-/- + mPTEN) had rescued the inhibitory effect of glutamine 
deprivation on cell viability at 0mM and 0.1mM. Statistical significance was 
calculated on wildtype vs. MEFPTEN-/- and MEFPTEN-/- + PTEN vs. MEFPTEN-/- + 
mPTEN at that particular glutamine concentration. B. The inhibitory effect of 
glutamine deprivation on the cell viability in human breast cell line with PTEN/Akt 
aberration. MCF10Ca1a with PTEN/Akt dysregulation (described in Chapter 4) 
had lower relative cell viability as compared to normal counterpart, MCF10A1 at 0 
and 0.05mM of glutamine. * p < 0.05, ** p < 0.01 and # p < 0.005 for n = 3.  
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5.2.2 Molecular mechanism of glutamine addiction in PTEN aberrated cell 
lines 
It has been reported previously that c-Myc enhances glutamine metabolism by up-
regulating mitochondrial glutaminase expression [69]. To study the mechanism 
which underlies the regulation of glutamine metabolism by PTEN/Akt, we first 
examined the mRNA level of the kidney-isoform of glutaminase (KGA), which 
had been implicated in tumorigenesis [183]. As shown in Fig. 5.2.2A. lower KGA 
mRNA was observed in MEFPTEN-/- and MEFPTEN-/- with mutant PTEN over-
expression as compare to wildtype and with MEFPTEN-/- full-length PTEN over-
expression. Notably, the differences in the fold change of KGA mRNA was 
consistently 3-fold between MEFs with or without PTEN (3-fold lower in 
MEFPTEN-/- vs. MEFWT and 3-fold higher in MEFPTEN-/- + PTEN vs. MEFPTEN-/- + 
mPTEN) (Fig. 5.2.2A). Furthermore, the KGA mRNA level was correlated to c-
Myc protein expression which was found lower consistently in the MEF cells 
without functional PTEN (Fig. 5.2.2B). Taken together, the results showed that c-
Myc and KGA were inversely correlated with PTEN status. In view of this we 
concluded that glutamine addiction in PTEN/Akt dysregulated cells appeared to be 










Fig. 5.2.2 PTEN/Akt-mediated glutamine addiction is independent of KGA 
and c-Myc A. A lower relative KGA mRNA level was observed in MEFPTEN-/- vs. 
wildtype and MEFPTEN-/- + mPTEN vs. MEFPTEN-/- + PTEN. A consistent 3-fold 
different in the mRNA level was observed in MEFs with or without functional 
PTEN. * p < 0.05, ** p < 0.01 and # p < 0.005 for n = 3. B. Lower c-Myc protein 
expression in MEFPTEN-/- (lane 4) and MEFPTEN-/- + mPTEN (lane 1a, b and c) as 
compared to wildtype (lane 3) and full length PTEN over-expression in MEFPTEN-/- 





5.2.3 Redox imbalance and therapeutic opportunity in PTEN/Akt 
dysregulated cell lines. 
We next explored the importance of glutamine metabolism in conferring a growth 
advantage to the PTEN/Akt dysregulated cells. We had previously reported a 
higher ROS production in PTEN dysregulated cell lines (manuscript in 
preparation/Chapter 4). In this study, we confirmed a redox imbalance in the 
PTEN/Akt dysregulated cells: MnSOD and catalase were up- and down-regulated, 
respectively, in MEFPTEN-/- (Fig. 5.3.3A). Given that MnSOD dismutases 
superoxide to H2O2, which is then decomposed by catalase to form water and 
oxygen. The alteration in the antioxidant proteins in MEFPTEN-/- may result in 
higher ROS level, specifically, the H2O2 production. Indeed, as shown in Fig. 
5.2.3B, a higher rate of H2O2 release was observed from MEFPTEN-/- as compared to 
wildtype. In view of the inability of PTEN/Akt dysregulated cells to remove 
excessive H2O2, we further exploited the redox imbalance by providing exogenous 
H2O2 to the cells. Particularly, glutathione depletion (using buthionine 
sulphoximine, BSO, an inhibitor of glutathione biosynthesis) together with H2O2 
supplement had more pronounced reduction of the cell viability in MEFPTEN-/- as 
compared to wildtype (Fig. 5.2.3C). Given that glutamine is implicated in 
glutathione biosynthesis [63, 78], these preliminary data suggest that the glutamine 
addiction in the PTEN/Akt dysregulated cells may play an important role in redox 










Fig. 5.2.3 Redox imbalance and therapeutic opportunity in PTEN/Akt 
dysregulated cell lines. A. MnSOD and catalase protein expressions in MEFs. 
Higher MnSOD and lower catalase expressions were observed in MEFPTEN-/- as 
compared to wildtype. B. The rate of H2O2 production. The H2O2 production in 
MEFs was measured using the Amplex red assay kit according to the 
manufracturer's instruction. MEFPTEN-/- had higher H2O2 production as compared to 
the wildtype. Data represent technical triplicates. C. Cell viability of MEFs treated 
with BSO and H2O2. BSO (0.1mM) had sensitized MEFPTEN-/- toward H2O2 at 









 Rapidly proliferating cancer cells display remarkable energetic and 
biosynthetic demands. To meet this end, many if not all tumors exhibit abnormal 
high glucose consumption with most of glucose being secreted as lactate, even in 
the presence of oxygen (Warburg effect) [6]. Notably, the contemporary 
knowledge in cancer metabolism has further expanded beyond glucose metabolism. 
Particularly, recent studies have underlined the importance of glutamine 
metabolism in tumor development [62-64, 71, 72, 123, 181]. In this preliminary 
study, we showed that the PTEN/Akt dysregulated cells had increased glutamine 
dependency for proliferation. This glutamine addiction appeared to be independent 
of c-Myc and the kidney-isoform of glutaminase (KGA). Furthermore, our data on 
the reduction of the cell viability by BSO and H2O2 has alluded that glutamine may 
be important for glutathione biosynthesis in PTEN/Akt dysregulated cells. 
 Proliferation in multicellular organisms is controlled by signal transduction 
pathways, upon stimulation by growth factors or by constitutive activation of these 
pathways through oncogenic mutations [184]. Constitutive activation of Akt, 
commonly due to the loss of PTEN is implicated in a spectrum of cancers [7]. In 
addition to its anti-apoptotic property [185], Akt stimulates nutrient uptake to 
support rapid cell growth [186]. While c-Myc [69] and Kras [181] are implicated in 
cancer glutamine metabolism, the role of Akt in this altered cancer phenotype is 
unknown. The mouse embryonic fibroblast with PTEN knockout used in this study 
provides an excellent model to study any metabolic alteration resulting from an 
aberration in PTEN/Akt signaling. We had previously reported that increased 
respiratory functions (Chapter 3 and [28]) as well as ROS production (Chapter 4 
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and manuscript in preparation) in MEFPTEN-/-. In this study, we further 
demonstrated the redox imbalance in PTEN/Akt aberrated cells was probably 
resulted from the alterations in the antioxidant proteins, MnSOD and catalase. In 
fact, MnSOD has been shown to be up-regulated by Akt via FOXO3a to protect 
cell from oxidative stress [187]. The up-regulation of MnSOD by Akt might lead to 
enhanced production of  H2O2, which has been demonstrated to down-regulate 
catalase via PI3K/Akt/FOXO1 signaling [188]. These previous studies further 
supported our observation on the higher H2O2 production in in PTEN/Akt 
dysregulated cells. Given that ROS is essential for tumorigenesis [88], targeting the 
redox imbalance in cancer may provide anti-cancer therapeutic benefits. 
 Glutamine addiction in cancers has emerged as an attractive area of 
research in cancer metabolism. Glutamine has been recently shown to play a 
critical role in redox homeostasis in cancers [63, 78]. These studies have rekindled 
the interest in the cellular function of glutamine which was generally known as a 
source of reduced nitrogen for the synthesis of nucleotide and non-essential amino 
acids [64]. In addition, glutamine enters the TCA cycle and replenish malate for 
NADPH production via cytosolic malic enzyme [181]. Moreover, glutamine is 
involved in glutathione biosynthesis [78]. Both of these functions of glutamine 
highlighted its role in redox modulation. 
 The discovery of glutaminase isoforms had open another exciting revenue 
for the research in glutamine metabolism [189]. Particularly, the kidney-isoform of 
glutaminase (KGA) and its splice variant, glutaminase C (GAC) are implicated in 
cancers [69, 183, 190]. The down-regulation of KGA mRNA in hyper-proliferative 
MEFPTEN-/- in this preliminary study could be due to transcriptional-independent 
regulation of KGA. As we had previously demonstrated that higher respiratory 
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complexes proteins were controlled at protein translational level through 4E-BP1 
but not at gene transcriptional level [28]. Alternatively, it is possible that KGA is 
not implicated in the PTEN/Akt-regulated glutamine addiction. The latter 
commensurate the observation with the results on the lower c-Myc protein 
expression in PTEN knockout MEF. In contrast to previous study [69], our data 
suggested that the c-Myc-KGA axis may not be mediating the PTEN/Akt signaling 
on glutamine metabolism.  
 In conclusion, we showed for the first time that the PTEN/Akt dysregulated 
cells increased glutamine metabolism to coop with oxidative stress for survival. 
While our preliminary data showed the glutamine addiction in PTEN/Akt 
dysregulated cell may be independent of c-Myc-KGA axis, more work is required 
to confirm this observation as well as to identify the mechanism underlies the 








5.4 EXPERIMENTAL PROCEDURES 
Cell culture  ̶  MEFs and MCF10A series cell lines were cultured as described in 
previous chapters. 
Cell viability assay  ̶  This was carried out as described in previous chapter.  
Western-Blot  ̶  Protein expressions of c-Myc, MnSOD, catalase and α-tubulin were 
probed as described previously [28]. 
KGA mRNA ̶  The mRNA level of KGA in MEFs was quantified as described 
previously [28] using forward primer: 5'-TCTCTTCCTCTACTGCCTAAC-3' and 
reverse primer: 5'-CAACCCAACCCAACCAAA-3'. Since the spliced-isoform 
glutaminase C (GAC) lacks of exon 16-19 as compared to kidney-type glutaminase 
(KGA) [189], these primers were designed at exon 18 recognised specifically KGA 
but not GAC. 
The rate of H2O2 production  ̶  H2O2 generated from MEFs (10, 000 cells per 96-
well) was determined using the Amplex® Red assay kit (InvitrogenTM) according 
to the instruction from the manufacturer. In the presence of peroxidase, the 
Amplex® Red reagent reacts with H2O2 from the cells in a 1:1 stoichiometry to 
produce the red-fluorescent-oxidation product, resorufin which was then detected 




CHAPTER 6 A SIMPLIFIED ASSAY OF AZIDE-




 PTEN is best known as a powerful tumor suppressor to protect organisms 
against cancers. To a greater extent, the beneficial effects of PTEN outstretch 
beyond preventing cellular transformation. For instance, PTEN has been reported 
to improve longevity [191] and energy expenditure [191, 192]. Given that the 
longevity depends heavily on energy expenditure/mitochondrial functions [191, 
193], it is not surprising that energy expenditure/mitochondrial functions decline as 
we age [194]. Moreover, the loss of PTEN is associated with aging [195]. In 
contrast to previous chapters which examined the role of PTEN/Akt signaling in 
mitochondrial functions from the perspective of tumorigenesis, this chapter aimed 
to examine a possible relationship between PTEN and mitochondrial respiratory 
functions in aging model. We were interested in cytochrome c oxidase (COX) 
activity as an indicative "biomarker" as COX deficiency is a common defect in 
mitochondrial diseases [196].  
 Given there is limited correlation between genomic/proteomic alterations and 
clinical phenotypes [197-199], the assay of COX enzymatic activity appears to be 
of high clinical relevance. However, the existing protocols for COX activity lack 
accuracy and reproducibility. Particularly, COX activity measurement by the 
spectrophotometric approach has been associated with large inter- and intra-
laboratory variation [200]. The shortcomings could be due to: 1) lack of a stirring 
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system which causes uneven distribution of particles, bubble formation and/or 
mitochondrial bursting [201, 202], which interfere with absorbance reading; 2) 
product inhibition by rapid formation of oxidized cytochrome c (cyt c) [201] due to 
high mitochondrial protein concentration used [200]; 3) the problematic rapid 
kinetics arising from the complicated oxidase activity spectrum so that the pseudo 
first-order rate constant of the reaction has to be assumed [203]. This parameter is 
hard to estimate and is usually subjected to analytical errors. Furthermore, the 
assumption is not valid under many assay conditions [203]; 4) the measurement 
does not allow the inhibitor-sensitivity to be carried out within the same run, which 
may explain why most of the studies did not show cyanide/azide-sensitive COX 
activity [200], although it is recommended [204]. 
 In view of the intrinsic confounding properties of the spectrophotometric 
assay, we adopted the alternative polarographic method [205-207] (Scheme 1) to 
measure COX activity. Unfortunately, this protocol too, has several pitfalls as 
described below. 
Scheme 1. Protocols for COX activity in polarographic assays 
Conventional  
cytochrome c + mitochondrial extract        ascorbate  + TMPD 
Modified  





6.2 RESULTS AND DISCUSSION 
 Following the conventional polarographic assay, a rapid increase in the rate 
of oxygen consumption (O2 flux) was observed upon the addition of 5mM of 
ascorbate (asc) and 0.25mM N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD) 
to an assay mixture containing 10μM cyt c and 5μg of rat liver mitochondrial 
protein (mito) (Fig. 6.2.1). The O2 flux was not sustainable but gradually declined 
(indicated by an asterisk).  An attempt to inhibit the COX activity with 5mM 
potassium cyanide (KCN, a known inhibitor of COX) elicited a rapid stimulation 
of the O2 flux. This anomalous action of KCN suggested that the increased O2 
consumption might not be contributed by COX. Indeed, the same observation was 
made in the absence of mitochondrial protein extract (Figure 6.2.3). As KCN is 
basic (pH 11), a pH adjustment is necessary since the rate of auto-oxidation of asc 
and TMPD is known to be increased at an alkaline pH [208, 209]. Although the 
pH-adjusted KCN produced less oxidation of ascorbate as compared with the 
original stock solution, it too, failed to inhibit COX activity (data not shown). 
Furthermore, the inhibitory action of KCN is known to be compromised by the 
formation of cyanohydrins with keto acids, such as pyruvate and α-ketoglutarate 
[210], which are normally present in tissues at high micromolar concentrations 
[211]. Given the problems encountered in the conventional polarographic assay, 




Fig. 6.2.1 Anomalous action of KCN in the conventional polarographic assay 








Fig. 6.2.2 Our modified polarographic assay of azide-sensitive COX activity 
measured by using (A) an Oxygraph-2k and (B) a Clark oxygen electrode. The 
rate of auto-oxidation of reduced cyt c (cyt cred) was represented by “x” and the 
azide-sensitive COX activity was calculated by the difference in O2 flux before and 






 Essentially, the modified polarographic assay comprises the sequential 
addition of reduced cyt c (a natural endogenous electron donor), mitochondrial 
extract and sodium azide (Scheme 1). This protocol accounts for the auto-oxidation 
of reduced cyt c (x) and azide-sensitivity (y-z) (Figure 6.2.2A and B) in a single 
experiment. Previous studies have emphasized that the spontaneous oxidation of 
any reducing chemical in a COX assay mixture requires appropriate background 
subtraction [131, 203, 212-214]. This non-enzymatic oxidation (y-x) of reduced cyt 
c could contribute to as much as 50% of the total oxygen consumed (Figure 6.2.2A 
and B); which is of a similar order of magnitude as the chemical background of 
TPMD + ascorbate with or without cyt c in intact cells [214]. Furthermore, the 
modified protocol could also be used on a Clark oxygen electrode. Being less 
sensitive compared to the Oxygraph-2k, a higher amount of protein was required 
(5μg in Oxygraph-2k vs. 50μg in Clark oxygen electrode) which resulted in a lower 
value of COX activity. This might be attributed by product inhibition with higher 






Fig. 6.2.3 Non-enzymatic and KCN-induced oxidation of ascorbate ± TMPD 
monitored by polarography. In the absence of an enzyme extract, the 
spontaneous oxidation of ascorbate ± TMPD was evident and this was further 
induced by the addition of 5mM KCN.  
 
 
Fig. 6.2.4   End-product inhibition at high enzyme concentration. When 70µg 
protein of rat liver mitochondrial (mito) extract was used under the same conditions 
as in Figure 6.2.1,  a rapid increase in oxygen flux could be observed but this was 
not sustainable unlike when 5µg protein was employed (Figure. 6.2.2A). This 
difference could be due to the well-known end-product feedback inhibition of COX 
















Healthy (53yr) 288.4 ± 14.3 
Diabetic (57yr) 65.5 ± 17.5# 
Female 
Healthy (53yr) 673.7a 
Diabetic (51yr) 283.1 ± 76.4 
Neuro-2a 
 
undifferentiated 499.2 ± 171.8 
differentiated 977.6 ± 95.1* 
C.elegans 
 
young (4 days) 1309.6 ± 105.8 
old (10 days) 837.6 ±106.3** 
 
Table 6.1 Measurement of COX activities in human platelets, Neuro-2a cells 
and C. elegans using our modified polarographic assay. The difference in COX 
activity was significant between each of the respective sets of data, as shown by * p 
< 0.05, ** p < 0.01 and # p < 0.005 for n=3. a represents only one measurement due 
to sample limitation. 
 
 In our assay, all the reactions in the sequential steps are quantified in a real-
time manner within a single experiment. While it is necessary to determine the 
cyanide/azide sensitivity when measuring COX activity, a separate run is often 
required in spectrophotometric assays, which poses a technical problem when the 
sample is limited. As compared to our previous study, an approximately 10-fold 
higher  mitochondrial protein was required in the spectrophotometric COX assay 
[28]. Under these conditions, the fast depletion of reduced cyt c and the rapid 
accumulation of its oxidized form can lead to product inhibition [201]. Indeed, our 
observation of an unsustainable O2 flux, which collapsed immediately when high 
enzyme protein was used (Figure. 6.2.4) further supported this phenomenon. 
Indeed, it has been shown that less enzyme could linearize the rate of the reaction 
[201] and less reduced cyt c is needed [203]. Therefore more replicates could be 
accommodated for valuable human biopsy or biological samples. In addition, our 
azide-sensitive COX activity has a smaller coefficient of variation (CV) as 
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compared to spectrophotometric assay (Table 6.2) which implied a higher degree of 
accuracy and reproducibility. However, no attempt was made to compare the 
specific activities as the two assays were based on quite different assays conditions, 
which could give “different and sometimes conflicting” results, as previously 
cautioned [203]. Nevertheless, the pseudo-first order kinetics and other interfering 
factors might over-estimate the COX activity measured in spectrophotometric 




Table 6.2  Comparison of COX activity of mouse embryonic fibroblasts 
(MEFs) and coefficient of variation (CV) obtained by the conventional 
spectrophotometric and our modified polarographic assays. Data of COX 
activities of MEFs measured by the spectrophotometric procedure was reproduced 
from [28] which had a higher coefficient of variation (CV) as compared with our 
modified polarographic assay.  COX activity measured by both assays was 52-42% 








 To explore the potential application of our modified assay, COX activity 
was measured in diverse biological samples (Table 6.1). Lower COX activity was 
observed in human platelets from diabetic subjects as compared with the respective 
age- and sex-matched healthy control subjects. However, the limited sample size 
precludes statistical analysis although our data suggests a possible impairment of 
COX activity, presumably from mitochondrial dysfunction in diabetes [215]. 
Lower COX activity has also been associated with age-related neurodegenerative 
Alzheimer’s and Parkinson’s diseases [216]. Using a mammalian neuronal cell line 
Neuro-2a, a higher COX activity was observed in differentiated compared to the 
undifferentiated cells, which could be due to the enhanced mitochondrial 
biogenesis of neuronal cells upon differentiation [217, 218]. Given that the 
nematode, C.elegans is an established animal model for aging, the significantly 
lower COX activity in old (10 days old) as compared to young (4 days) led us to 
propose that COX activity could serve as a "biomarker" for aging.  
 To summarize, the modified polarographic measurement of azide-sensitive 
COX activity (Figure. 6.3)  requires less enzyme and cyt c, which (a) eliminates 
end-product inhibition and (b) can accommodate replicate assays when the tissue is 
limited which is usually the case with human samples. Furthermore, a lower CV 
was achieved indicating a greater degree of accuracy and reproducibility. 
Polarographic analysis has the added advantage of a built-in stirring system; it 
disperses protein particles which tend to aggregate. The aggregation phenomenon 
has been highlighted to influence COX measurements [202, 219]. The main 
limitation of our assay is that the high-resolution respiratory equipment is normally 
not available in most laboratories; however, with adequate samples, the Clark 
oxygraph can be employed. Although our data on C.elegans described above 
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provide a plausible relationship between COX activity and aging, more work is 
necessary to establish unequivocally a direct association of the two as well as with 
the profile of PTEN in the future. 
 
 
Fig. 6.3 Schematic diagram of the simplified azide-sensitive assay of 
cytochrome c oxidase.  This protocol allows accurate determination of COX 
activity by taking into account the auto-oxidation of the natural electron donor, the 








6.4 EXPERIMENTAL PROCEDURES 
6.4.1 Materials 
Reagents  




Mouse embryonic fibroblasts (MEFWT and MEFPTEN-/-) were cultured as described 
in Chapter 3. The murine neuroblastoma Neuro-2a (differentiated and 
undifferentiated) and C. elegans were cultured as described previously [220, 221]. 
Human blood was collected from diabetic patients and from age- and sex-matched 
healthy subjects with approval from the Domain Specific Review Board (DSBR) 
for blood collection from the National University Health Services (National 
University of Singapore). Briefly, heparin-treated blood was first layered onto 
Histopaque®-1077 (Sigma) followed by centrifugation at 400 xg for 30 min. The 
upper layer was transferred to a new tube and centrifuged at 2500 xg for 20 min to 
collect the platelets, which were washed twice in 0.25 M sucrose and kept at -80oC 
until use.  
Isolation of mitochondria from cells and C.elegans  
Isolation of mitochondria was carried out as described in Chapter 3 for MEF, 
Neuro-2a and C. elegans; however, the last required 60 up-and-down strokes of 
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homogenization. The rat liver mitochondrial fraction was prepared as described 
previously [133]. All mitochondrial extracts and human platelets were subjected to 
three freeze-thaw cycles prior to the experimentation. Protein concentrations were 
determined by the bicinchoninic acid assay (Pierce®, Thermo Scientific, Rockford, 
US). 
Assay conditions 
(a) Spectrophotometric assay: COX activity was determined by following the rate 
of decrease of reduced cytochrome c (cyt cred) at 550 nm in a Beckman Coulter 
DU® 800 spectrophotometer (Brea, CA).  Cyt c was first reduced by ascorbate 
following the procedure described previously [131], without the subsequent 
removal of ascorbate. 
(b) Conventional polarographic assay:  The order of addition we adopted was: cyt c, 
mitochondrial extract, 5mM ascorbate and 0.25mM TMPD. This sequence was a 
modification of the original assay [203], which has been varied by different groups 
in the past in terms of the order of addition and the concentrations of the reactants 
[205-207].  
(c) Our modified azide-sensitive polarographic assay: reduced cytochrome c (Cyt 
cred) (65-70 μM) was first added to the chambers containing MiR05 buffer [125]. A 
steady O2 flux was recorded, which represents the spontaneous oxidation of cyt cred 
(and possibly any residual ascorbate, denoted as "x" in Figure 6.2.2A and B). This 
was followed by the introduction of different biological samples containing 5-70 
μg protein and finally 50 mM sodium azide, a known specific COX inhibitor. The 
difference in O2 flux before ("y" in Figure 6.2.2A and B) and after the addition of 
sodium azide ("z" in Figure 6.2.2A and B) denotes the azide-sensitive COX 
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activity. Both the Oxygraph-2k (Oroboros, Innsbruck, Austria) and a Clark oxygen 
electrode (Hansatech, Norfolk, UK) were used in this study. 
Statistical analysis 
The coefficient of variation (CV) was calculated as a ratio of the standard deviation 
(σ) to the mean (μ) (CV = σ/μ) [222]. The CV value was adopted as it allows for a 
comparison of the variation relative to the mean between data sets which are 
expressed in different units [222]. The data are presented as the mean ± SD, and 
were analyzed by the two-tailed Student's t-test, where a p value of < 0.05 was 











CHAPTER 7 GENERAL DISCUSSIONS, 
CONCLUSIONS AND FUTURE DIRECTIONS 
7.1 GENERAL DISCUSSIONS 
 The contemporary knowledge in cancer metabolism is advancing by leaps 
and bounds. The ever updating new information from this area provides a number 
of exciting paradigms in dissecting the Achilles' heel in cancers. Nevertheless, the 
astonishing achievements today were not possible without the ground-breaking 
discovery by the great scientist  ̶  Otto Warburg, who described for the first time 
over 80 years ago the altered glucose metabolism in cancer cells. Since then, 
numerous studies have contributed to a better understanding of this bizarre cancer 
phenotype. The fruitful results from those studies in combination with the 
discovery of oncogenic signalings have further propelled the cancer metabolism 
research into a new era. 
 Our study described in Chapter 3 demonstrated for the first time that the 
PTEN/Akt oncogenic signaling interplayed with respiratory functions via protein 
translation pathway [28]. Given that Akt stimulates aerobic glycolysis [5], its role 
in respiratory functions is pertinent with regards to the Warburg's hypothesis: 
aerobic glycolysis in cancer is due to the impairment in respiration [6]. Notably, we 
found that Akt stimulates aerobic glycolysis not at the expense of respiratory 
functions. Rather, Akt further enhanced respiratory capacity. However, a 
comparable basal oxygen consumption between wildtype and MEFPTEN-/- has 
further alluded that the hyper-proliferative cells with PTEN/Akt aberration may 
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manifest a metabolic phenotype somewhat similar to the Warburg effect. 
Particularly, we observed lower pyruvate dehydrogenase (PDH) activity in 
MEFPTEN-/- as compared to wildtype (unpublished observation and [223]) which 
may result in a lower acetyl-coA for the TCA cycle. The latter may explain the 
comparable oxygen consumption in MEFs even though MEFPTEN-/- had higher 
respiratory capacity.  
 Following from the observation made in Chapter 3 concerning the lower 
proton leak in MEFPTEN-/-, we further extended the study to examine the effect of 
PTEN/Akt on mitochondrial membrane. As shown in Chapter 4, higher 
mitochondrial cholesterol level was correlated to lower proton leak. Notably, we 
found the novel role of mitochondrial cholesterol is to enhance the ROS production 
through the reduction of proton leak. Our results from Chapter 4 provides the 
molecular mechanism by which the cholesterol-lowering drugs, such as the statins 
exert their anti-cancer property [167] via decreasing ∆ ψm and ROS production. As 
both the ∆ ψm [152, 224, 225] and ROS [177] are often found up-regulated in 
cancers, our data on ROS reduction by mitochondrial cholesterol deprivation 
supports the "uncoupling and survive" hypothesis proposed by Brand [166].  
 While the oncogenic signaling from PTEN/Akt has been shown to stimulate 
ROS for the proliferation and survival of the cells (Chapter 3 and 4), it is 
conceivable that the antioxidant adaptative mechanisms may be promoted by the 
oncogenic signaling concurrently to minimize the oxidative stress [177]. Given that 
the glutamine addiction has recently been shown to be implicated in c-Myc- or 
Kras-mediated redox modulation [69, 181], we sought to study the effect of 
PTEN/Akt signaling on glutamine metabolism and redox regulation. As described 
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in Chapter 5, we showed for the first time that PTEN/Akt rendered cells to 
glutamine addiction. Given that glutamine can be directly involved in glutathione 
biosynthesis [63, 78], the reduced cell viability by the glutathione depletion had 
further alluded that glutamine dependency in PTEN/Akt dysregulated cell may be 
critical to counter the redox imbalance. Indeed, our preliminary data on the 
reduction of cell viability in MEFPTEN-/- with glutathione depletion and H2O2 
treatment further demonstrated the potential therapeutic benefit of targeting 
glutamine metabolism in PTEN/Akt dysregulated cells. Therefore, inhibition of 
glutamine metabolism in tumor cells with PTEN/Akt aberration can be potentially 
synergized with therapies that increase intracellular reactive oxygen species, such 
as chemotherapy and radiation to further improve the clinical outcome. 
Furthermore, our preliminary data from Chapter 5 showed that despite KGA is 
implicated in c-Myc and Kras-mediated glutamine addiction in cancers [69, 181], it 
might be dispensable in PTEN/Akt-mediated glutamine addiction, suggesting that 
the regulation of the glutaminase isoforms is oncogenes-specific. Hence, the 
profiling of the oncogenic signaling involved in the tumor prior to the treatment 
may favor the clinical efficacy. Conceivably, such personalized-targeted therapy is 
possible with several distinct inhibitors of the glutamine isoforms are currently 
being developed [62, 226]. 
 Last but not least, Chapter 6 provides an alternative method to measure 
cytochrome c oxidase (COX) activity. While most the COX activity assays were 
developed long ago and appeared to serve adequately the research in this area, we 
are particularly disappointed with the high amount of protein required for the 
spectrophotometric assay. Using the polarographic approach, we modified the 
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protocol for the COX measurement. Notably, the modified assay provided a better 
measurement in term of the accuracy and sensitivity as compared to the rest of the 
conventional spectrophotometric and polarographic assays available. Furthermore, 
while the biomarker of aging remains elusive, our data on old and aged C. elegans 
and skin fibroblasts (data not shown) alluded that COX could serve as one of the 
biomarkers for aging. Given that most of the assay kits were developed based on 
spectrophotometric approach, our modified polarographic assay for COX activity 












 Taken together, the study described in this thesis had unveiled several novel 
molecular mechanisms in which PTEN/Akt interplays with the mitochondrial 
respiratory functions. Using combinatorial approaches, we dissected the effects of 
PTEN/Akt signaling on respiration, mitochondrial membrane regulation, ROS 
production and glutamine metabolism. The mechanisms by which PTEN/Akt 
regulates mitochondrial respiratory functions are depicted in Fig. 7.2. The 
conclusion drawn from this study may provide valuable information to the 
contemporary knowledge on the relationship between oncogenic signaling of 






Fig. 7.2 The pleiotropic effects of PTEN/Akt signaling on respiratory functions.  
PTEN knockout in mouse embryonic fibroblasts (MEFPTEN-/-) results in an 
accumulation of PIP3 produced by PI3K at the plasma membrane. The elevated 
level of PIP3 could be restored or suppressed by over-expression of PTEN 
(described in Chapter 6). PIP3 on the plasma membrane recruits both the Akt and 
phosphoinositide-dependent protein kinase 1 (PDK1) via their pleckstrin homology 
(PH) domains. The membrane recruitment facilitates the phosphorylation of Akt at 
Ser473 by mTORC2 and that at Thr308 by PDK1 and leads to a fully activated Akt 
which then phosphorylates mTORC1. As a downstream target of mTORC1, 4E-
BP1 is then phosphorylated by mTORC1 and become inactive as a repressor of 
protein translation. This leads to the initiation of protein translation of RC 
components and contributing to enhanced OXPHOS in MEFPTEN-/- (Chapter 3) as 
well as ROS production (Chapter 4 and 5). The hyperactivated Akt also enhanced 
mitochondrial cholesterol content which results in a lower proton leak. The lower 
proton leak is associated with higher ∆ ψm which serves as the driving force for 
ROS production (Chapter 4). Glutamine metabolism is up-regulated by PTEN/Akt 
signaling probably due to the increased in antioxidant demand to temper the high 
amount of ROS generated (Chapter 5). Taken together, PTEN/Akt enhances ROS 
production for cell survival and proliferation via up-regulated respiratory functions 
(contributed by both the enhanced OXPHOS and lower proton leak). The egregious 
ROS is removed by up-regulated antioxidant capacity (probably through glutamine 
metabolism, as described in Chapter 5) to prevent excessive oxidative stress.  
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7.3 FUTURE DIRECTION 
 Our study demonstrated in Chapter 3 highlighted the importance of 
Akt/mTOR/4E-BP1 in regulating mitochondrial respiratory functions via up-
regulating the protein translation of the RC. Notably, a similar observation was 
made in Drosophila, in which 4E-BP1 up-regulates RC I and IV for lifespan 
extension upon dietary restriction [19]. In addition, while S6K is dispensable for 
cancer formation, 4E-BP1 exerts a significant role in c-Myc-, Akt- and ERK-
mediated tumorigenesis [23, 24, 227]. Taken together, given that a number of 
proteins are under the umbrella of 4E-BP1-mediated cap-dependent translation, 
downstream targets of 4E-BP1 especially mitochondrial proteins warrant further 
investigation to identify the most prominent player(s) involved in the 4E-BP1-
mediated tumorigenesis. 
 Our work on the role of mitochondrial cholesterol on proton leak and ROS 
production has further unfolded the feasibility of using cholesterol-lowering drugs, 
the statins, in cancer prevention/treatment [167, 228]. Given that statins inhibit the 
formation of mevalonate, a precursor for the biosynthesis of various important 
molecules that contribute to diverse cellular functions, ranging from cholesterol, 
heme and ubiquinone synthesis to N-glycosylation and protein prenylation [170]. It 
is not surprising that a spectrum of side effects are associated with the statins which 
have reduced their clinical efficacy as an effective anti-cancer drug [168]. 
Therefore, the development of inhibitors to target downstream of HMG-CoA 
reductase, such as the squelene synthase to inhibit cholesterol biosythesis 
specifically may reduce side effects and improve clinical outcome. Furthermore, 
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our data on proton leak and ROS generation in conformity with the "uncoupling 
and survive" hypothesis [166], suggests that mild uncoupling by natural compound, 
such as curcumin [133] may have cancer preventive property . 
 While glutamine metabolism is a relatively new research area in cancer 
metabolism as compared to glucose metabolism as described by Warburg over 80 
years ago, it is gaining popularity concerning its role in redox regulation in cancers. 
Based on the preliminary data demonstrated in Chapter 5, we further proposed that 
glutamine metabolism inhibition in combination with radio- or chemotherapy that 
provokes ROS generation may improve clinical efficacy in treating the 
malignancies. More works are currently being carried out to further validate this 
hypothesis. Moreover, we showed that the regulation on glutamine isoforms  
appeared to be oncogene-specific warrants further investigation.  
 Last but not least, reduced COX activity in the aged C.elegans as described 
in Chapter 6 has widen the prospective in the search of the "biomarker" of aging. 
Given that the mitochondrial-targeted antioxidant MitoQ has improved COX 
activity in C.elegans models of Alzheimer's disease (manuscript in preparation), we 
further proposed that COX as a key player in aging. More studies on diverse 
biological models should be carried out in the future to further validate this 
hypothesis. This "biomarker" of aging may serve as a molecular readout for aging-
related research and possess invaluable potential in both clinical and cosmetic 
industry. 
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